US20170312247A1 - HERIPENES WITH PAIN-RELIEVING EFFECT, ACTIVE SUBSTANCES OF Hericium erinaceus MYCELIUM AND THE PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE HERIPENES OR ACTIVE SUBSTANCES - Google Patents
HERIPENES WITH PAIN-RELIEVING EFFECT, ACTIVE SUBSTANCES OF Hericium erinaceus MYCELIUM AND THE PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE HERIPENES OR ACTIVE SUBSTANCES Download PDFInfo
- Publication number
- US20170312247A1 US20170312247A1 US15/508,369 US201515508369A US2017312247A1 US 20170312247 A1 US20170312247 A1 US 20170312247A1 US 201515508369 A US201515508369 A US 201515508369A US 2017312247 A1 US2017312247 A1 US 2017312247A1
- Authority
- US
- United States
- Prior art keywords
- preparation
- pain
- erinaceus
- group
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 240000000588 Hericium erinaceus Species 0.000 title claims abstract description 85
- 239000013543 active substance Substances 0.000 title claims abstract description 53
- 208000002193 Pain Diseases 0.000 title claims abstract description 50
- 230000000694 effects Effects 0.000 title claims abstract description 46
- 235000007328 Hericium erinaceus Nutrition 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims description 29
- 239000000843 powder Substances 0.000 claims abstract description 16
- 238000000855 fermentation Methods 0.000 claims abstract description 13
- 230000004151 fermentation Effects 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 229920001817 Agar Polymers 0.000 claims abstract description 5
- 239000008272 agar Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 124
- 239000000284 extract Substances 0.000 claims description 69
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- YQAQVNZGKXQJMK-ACIBSNEHSA-N (1S,2R,5R,10R,16R,19S,20R,21R)-14,16,20-trihydroxy-2,5-dimethyl-8-propan-2-yl-18,22-dioxahexacyclo[17.2.1.02,10.05,9.013,21.016,20]docosa-8,13-dien-15-one Chemical compound CC(C)C1=C2[C@H]3CCC4=C(O)C(=O)[C@@]5(O)CO[C@H]6O[C@@H]([C@@H]4[C@@]56O)[C@]3(C)CC[C@@]2(C)CC1 YQAQVNZGKXQJMK-ACIBSNEHSA-N 0.000 claims description 25
- 230000036407 pain Effects 0.000 claims description 24
- 238000011534 incubation Methods 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000003570 air Substances 0.000 claims description 7
- 239000007789 gas Substances 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000002518 antifoaming agent Substances 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- 102000007466 Purinergic P2 Receptors Human genes 0.000 claims description 4
- 108010085249 Purinergic P2 Receptors Proteins 0.000 claims description 4
- 238000005273 aeration Methods 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 235000021374 legumes Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 3
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 65
- 239000000203 mixture Substances 0.000 description 46
- 238000000605 extraction Methods 0.000 description 45
- 102000005962 receptors Human genes 0.000 description 34
- 108020003175 receptors Proteins 0.000 description 34
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 31
- 238000000692 Student's t-test Methods 0.000 description 31
- 229910001424 calcium ion Inorganic materials 0.000 description 31
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 28
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 28
- 239000011575 calcium Substances 0.000 description 28
- 229910052791 calcium Inorganic materials 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 230000035484 reaction time Effects 0.000 description 25
- 230000020341 sensory perception of pain Effects 0.000 description 23
- 239000002609 medium Substances 0.000 description 22
- 229940003871 calcium ion Drugs 0.000 description 17
- 201000008968 osteosarcoma Diseases 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000002596 correlated effect Effects 0.000 description 12
- 230000003834 intracellular effect Effects 0.000 description 11
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 10
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 206010029260 Neuroblastoma Diseases 0.000 description 9
- 239000000730 antalgic agent Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 206010048010 Withdrawal syndrome Diseases 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 206010065390 Inflammatory pain Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 208000028591 pheochromocytoma Diseases 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 0 *O/C1=C2\CC[C@]3([H])C4=C(C(C)C)CC[C@]4(C)CC[C@@]3(C)[C@@]3([H])O[C@]4([H])OC[C@](O)(C1=O)[C@]4(O*)[C@]23[H] Chemical compound *O/C1=C2\CC[C@]3([H])C4=C(C(C)C)CC[C@]4(C)CC[C@@]3(C)[C@@]3([H])O[C@]4([H])OC[C@](O)(C1=O)[C@]4(O*)[C@]23[H] 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- QQGBNWZSDRWZHX-UHFFFAOYSA-N CC(C)C1=C2C3CCC4=C(O)C(=O)C5(O)CCC6OC(C4C65O)C3(C)CCC2(C)CC1 Chemical compound CC(C)C1=C2C3CCC4=C(O)C(=O)C5(O)CCC6OC(C4C65O)C3(C)CCC2(C)CC1 QQGBNWZSDRWZHX-UHFFFAOYSA-N 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229930191277 erinacine Natural products 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- XNOBOKJVOTYSJV-KQYNXXCUSA-N [[(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XNOBOKJVOTYSJV-KQYNXXCUSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000004720 cerebrum Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- -1 erinacines A Natural products 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000003594 spinal ganglia Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- CAWZRIXWFRFUQB-IOSLPCCCSA-N α,β Methylene ATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CAWZRIXWFRFUQB-IOSLPCCCSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000007074 Phospholipase C beta Human genes 0.000 description 2
- 108010047834 Phospholipase C beta Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102000002298 Purinergic P2Y Receptors Human genes 0.000 description 2
- 108010000818 Purinergic P2Y Receptors Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- SSCDRSKJTAQNNB-WVZYQCMWSA-N [3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC SSCDRSKJTAQNNB-WVZYQCMWSA-N 0.000 description 2
- PGAVKCOVUIYSFO-UHFFFAOYSA-N [[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 229960004484 carbachol Drugs 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000007372 neural signaling Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- 101150104241 ACT gene Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000123222 Hericium Species 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 241000959662 Hydnaceae Species 0.000 description 1
- 108091008585 IP3 receptors Proteins 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 240000000359 Triticum dicoccon Species 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004678 mucosal integrity Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/11—Preparation or pretreatment of starting material involving culturing conditions, e.g. cultivation in the dark or under defined water stress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Definitions
- the present invention is related to an active substance with a pain-relieving effect, in particular, an active substance originated from Hericium erinaceus.
- the generation of nociception involves the transduction of pain signals on a series of neural pathways, finally arriving at the cerebrum, so that a human body feels pain.
- the neural transduction pathway of nociception starts from the generation of stimulation, followed by transforming this stimulation into neurosignals by nociceptors.
- the neurosignals are transmitted to the dorsal root ganglion (DRG), followed by transmission to the spinal cord and finally arrive at the nociception area in the thalamus of the cerebrum.
- DRG dorsal root ganglion
- P2Rs P2-purinoceptors
- the sensory nerves the sympathetic nerves, the parasympathetic nerves and the central nervous system, wherein the P2Rs on the sensory nerves are mainly the P2X 3 receptor (P2X 3 R) and the P2X 2/3 receptor (P2X 2/3 R).
- P2X 3 R the P2X 3 receptor
- P2X 2/3 R the P2X 2/3 receptor
- P2X 3 R, P2X 4 receptor (P2X 4 R) and P2X 7 receptor (P2X 7 R) are related to the nociceptor, pain transmission, inflammatory pain and neuropathic pain (Collier et al., Nature, 1966, 212(5060):411-412; Cockayne et at, Nature, 2000, 407(6807):1011-1015; Souslova et al., Nature, 2000, 407(6807):1015-1017; Jarvis and Burgard, Br. J.
- the ATP of the P2X 3 R gene knockout mice does not induce the neural electrical signal transduction on the DRG, and does block the peripheral nociception which is transmitted to the central nervous system (Cockayne et al., Nature, 2000, 407(6807): 1011-1015).
- the P2X 3 R antagonist can block the immediate pain, the inflammatory pain, and the visceral pain related to the neuropathic pain (Jarvis and Burgard, Br. J. Pharmacol., 2002, 135(6):1343-1344).
- mice do not show the pain-hypersensitivity induced by the physical damage and lack the neural signaling pathways transmitted to the spinal cord because of a peripheral nerve injury (Ulmann et al., J. Neurosci. 2008. 28(44):11263-11268).
- the P2X 7 R antagonist has the effect of reducing the neuropathic pain and the inflammatory pain (Honore, et al., J. Pharmacol. Exp. Ther., 2006, 319(3): 1376-1385).
- P2R based on its conformation and the signal transduction pathway, can be classified into two subfamilies, P2X 1 -P2X 7 (P2X 1-7 ) receptors and P2Y 1 -P2Y 14 (P2Y 1-14 ) receptors (Yang and Liang, Circ. Res., 2012, 111(4):397-401).
- P2X 1 -P2X 7 receptors has two transmembrane domains, and its C- and N-terminal regions are within the cell.
- P2X 1 -P2X 7 receptors the smallest one, P2X 4 R, has 388 amino acids, and the largest one, P2X 7 R, has 595 amino acids.
- the P2X receptor (P2XR) is a cationic channel receptor, allowing Na + and Ca 2+ to pass through. After the P2X receptor is stimulated, Ca 2+ flows into the cells through the P2XR, so as to increase the intracellular free calcium-ion concentration ([Ca 2+ ]c ⁇ ), which acts as a secondary signal to induce the subsequent physiological reactions.
- the neurosignals are sent to the thalamus of the cerebrum via the spinal cord to generate the nociception.
- the increased intracellular free calcium-ion concentration ([Ca 2+ ]c ⁇ ) further influences the cellular secretion. Concretely speaking, it may stimulate neuroimmunological cells to secrete cytokines.
- the P2Y 1-14 receptors are G-protein coupled receptors (GPCR).
- GPCR G-protein coupled receptors
- other P2Y subtypes are correlated to the G-protein (Gq). After actuation, Gq activates phospholipase C- ⁇ (PLC- ⁇ ) to cleave the phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3).
- the IP3 conjugates with the IP3 receptor on the endoplasmic reticulum (ER) of the cell and calcium ions stored in the ER are released, resulting in the increased intracellular free calcium-ion concentration ([Ca 2+ ]c ⁇ ).
- the P2XR and P2YR can both use the variations of the intracellular free calcium-ion concentration as an index for monitoring the receptor functions.
- Adenosine triphosphate (ATP) Adenosine triphosphate (ATP)
- ATP is a well-known energy-carrying and energy-transferring biomolecule. Szent-Gyorgyi found in 1929 that the ATP also has extracellular biological functions (Drury and Szent-Györgyi, J. Physiol., 1929, 68(3):213-237). In 1996, ATP was formally deemed as a neurotransmitter in the neuroscience field. ATP acts as a neurotransmitter for P2R on the P2R-related neuronal signaling pathways. When the nerves are stimulated, ATP releases from the synaptic vesicles to the synaptic cleft and stimulates the P2R on the neuron behind the synapse. Subsequently, ATP is quickly decomposed by enzymes in the synaptic cleft. The neurotransmission model above is also supported by the published literature as in the following examples.
- the analgesic market tends to become larger along with the aging population in society and gradual improvement to the requirements of quality of life.
- the ones that are hard to treat are neuropathy-induced neuropathic pain and cancer pain.
- One reason is that there are few efficient drugs that thoroughly inhibit pain.
- the relief of this long-term pain requires analgesics for long-term use.
- There are two main types of clinical analgesics one is morphine analgesics, and the other is non-narcotic analgesics. If patients are administered with a morphine analgesic for a long time, this could cause tolerance and dependence problems.
- Tolerance means that the efficiency of a drug will gradually attenuate along with an increase of the given dosage, and it is necessary to increase the given dosage to achieve the analgesic effect.
- Non-narcotic analgesics do not have adverse reactions (such as respiratory depression, habituation and so on) similar to narcotics, but have analgesic and anti-inflammatory functions and can decrease the rising body temperature (antipyretic function) to attenuate the inflammatory symptoms.
- These drugs are usually used to relieve the mild-to-moderate pain caused by diseases such as rheumatism, arthritis, ischialgia, degenerative arthritis and so on.
- These drugs are also the nonsteroidal anti-inflammatory drugs (NSAIDs) with the side effects of the simultaneous inhibition of cyclooxygenase-1 (COX-1) and COX-2.
- COX-2 When COX-2 is inhibited, the expression of prostaglandin 12 (PGI2) is decreased which results in the anti-inflammatory and analgesic functions and promotes the aggregation of blood platelets.
- PKI2 prostaglandin 12
- COX-1 is inhibited
- the mucosal integrity of the gastrointestinal tract is destroyed and the renal blood flow is influenced. This results in side effects such as stomach injury, kidney injury and so on, and inhibits the platelet aggregation which results in frequent bleeding. Therefore, analgesics' safety, side effects, addiction and sensitivity to tolerance are all problems to be solved, so as to develop a more excellent analgesic agent.
- erinaceus is classified in the kingdom Fungi, the phylum Eumycota, the subphylum Basidiomycotina, the class Basidiomycetes, the order Aphyllophorales, the family Hydnaceae, the subfamily Hericioideae, and the genus Hericium.
- H. erinaceus 's fruiting body has a soft and spherical appearance with many bars with rough protuberances.
- H. erinaceus is white when fresh and turns tawny after being dried.
- the H. erinaceus fruiting body or mycelia extract contains saccharides (Wang et al., Kaohsiung J. Med.
- erinaceus have effects on immunoregulation, blood lipid reduction, blood sugar reduction, the inhibition of gastric inflammation, or the occurrence of stomach cancer.
- 14 erinacines i.e. erinacines A, B, C, D, E, F, G, H, I, J, K, P, Q and R
- Erinacines can stimulate astrocytes in mice to secrete the neuron growth factors (NGF), so as to remedy diseases such as intellectual deterioration, neurodegeneration and so on.
- NNF neuron growth factors
- the inventors isolated, purified and identified novel compounds, i.e. heripenes, from the alcohol extract of the H. erinaceus mycelia, and proved in the experimental result that heripenes have the analgesia effect. The detail is described as follows.
- the purpose of the present invention is to disclose the heripene and a preparation method for an active substance of H. erinaceus , and the preparation is used to prepare the heripene, the active substance and a pharmaceutical composition containing the heripene or the active substance for a pain-relieving effect.
- the present invention discloses a preparation method for an active substance of H. erinaceus having an effect of relieving a pain, including the following steps of:
- step (b) inoculating the incubated mycelium of the H. erinaceus from step (a) into a medium in a flask and incubating at a temperature of 20-30° C. and pH 4.5-6.5 for 3-5 days;
- step (c) inoculating the incubated mycelium of the H. erinaceus from step (b) into a medium in a fermentation tank and incubating at a temperature of 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the mycelium of the H. erinaceus ;
- step (d) desiccating the fermented medium of the mycelium of the H. erinaceus from step (c) to obtain a powder of the mycelium of the H. erinaceus.
- an incubation in step (b) is a shaking incubation at a shaking rate of 100-250 rounds per minute (rpm).
- the fermentation tank in step (c) has a tank pressure of 0.8-1.2 kg/cm 2 and a stirring rate of 10-150 rpm, and a gas is introduced into the fermentation tank at an aeration rate of 0.5-1 volume per volume per minute (vvm).
- the gas is air, oxygen, carbon dioxide, nitrogen gas or a combination thereof.
- the medium used in step (b) and the medium used in step (c) are the same.
- the medium includes one or more combinations from a complex carbon and nitrogen source, animal or plant sources of protein or a hydrolyzate thereof, an inorganic salt, a saccharide, a yeast or a malt extract, and a defoaming agent.
- the complex carbon and nitrogen source is a grain or a legume
- the inorganic salt is a sulfate or a phosphate
- the powder of the mycelium of the H. erinaceus from step (d) is further extracted with an alcohol solvent to obtain an alcohol extract of the mycelium of the H. erinaceus.
- the alcohol solvent is an ethanol of 30-100 volume-volume percentage (v/v %) or a methanol of 30-100 v/v %.
- the alcohol extract of the mycelium of the H. erinaceus is further extracted with a water and an ethyl acetate, followed by a column chromatography to obtain the heripene having a structural formula (I) as follows:
- R is hydrogen, hydroxyl, C 1 -C 10 alkyl, C 1 -C 10 alkenyl or C 1 -C 10 alkynyl, which are optionally substituted with a substitute containing halogen, oxygen, nitrogen, phosphorus or sulfur; where the stereocenters at C-5, C-6, C-9, C-13, C-14, C-21, C22 and C-23 are an R-configuration or an S configuration.
- the functional group R being optionally substituted with a substituted means that two functional groups R can be individually or both substituted with a substitute containing halogen, oxygen, nitrogen, phosphorus or sulfur.
- the heripene when the group R of the heripene having the structural formula (I) is hydrogen, the heripene is the erinacine S having a structural formula (II) as follows:
- a ratio of water to ethyl acetate is 1:4.
- the pain for treatment in the preparation method above is a neuropathic pain or a cancer pain.
- a signaling pathway for the pain in the preparation method above includes a P2-purinoceptor (P2R).
- P2R P2-purinoceptor
- the present invention further discloses an active substance of the H. erinaceus having an effect of reducing a pain and being prepared by any one of the preparation methods above.
- the active substance of the H. erinaceus is powder after being prepared by the preparation method above.
- the active substance of the H. erinaceus is an alcohol extract after being prepared by the preparation method above.
- the active substance of the H. erinaceus is the heripene having a structural formula (I) after being prepared by the preparation method above.
- the heripene is the erinacine S having the structural formula (II) when R of the heripene of the structural formula (I) is hydrogen.
- the present invention further discloses a heripene compound having a structural formula (I).
- the heripene compound is the erinacine S having a structural formula (II) when R of the heripene compound of the structural formula (I) is hydrogen.
- the heripene compound above has a pain-relieving effect.
- the present invention further discloses a pharmaceutical composition having a pain-relieving effect, including an active substance of the H. erinaceus above, and a biologically acceptable carrier, excipient, diluent or adjuvant.
- the present invention further discloses a pharmaceutical composition having a pain-relieving effect, including a heripene compound above, and a biologically acceptable carrier, excipient, diluent or adjuvant.
- FIG. 1 illustrates an HPLC analytic spectrum of the erinacine S according to Embodiment 4.
- FIGS. 2(A), 2(B), 2(C), 2(D), 2(E) and 2(F) show the gene expression of the P2R receptors in the cells, which are monitored using the RT-PCR according to Item 2 of Embodiment 5.
- FIGS. 3(A), 3(B) and 3(C) show the calcium signals of the receptor in the cells, which are monitored after cells are filled with a fluorescent agent according to Item 1 of Embodiment 6, wherein (A) human osteosarcoma HOS cells, (B) rat pheochromocytoma PC12 cells, and (C) human neuroblastoma SH-SY5Y cells are stimulated with ATP and then with carbachol.
- FIG. 4 shows the calcium signals correlated with the P2XR subtypes in human osteosarcoma HOS cells according to Item 2 in Embodiment 2.
- FIGS. 5(A) and 5(B) show the calcium signals correlated with the P2YR subtypes in human osteosarcoma HOS cells according to Item 2 in Embodiment 2, wherein (A) the calcium signals are induced by ATP stimulation in a calcium free buffer, and (B) the calcium signals are induced by uridine triphosphate (UTP) stimulation.
- A the calcium signals are induced by ATP stimulation in a calcium free buffer
- UDP uridine triphosphate
- FIG. 6 shows the effect of the H. erinaceus mycelia alcohol extract on the ATP-stimulated P2R's calcium signals in the human osteosarcoma HOS cells according to Item 3 in Embodiment 6.
- FIGS. 7(A) and 7(B) show the inhibition effect of the calcium signals induced by (A) the alcohol extract and (B) the erinacine S treatments, followed by the ATP stimulation in the human osteosarcoma HOS cells according to Item 4 in Embodiment 6.
- FIG. 8 shows the comparisons between groups in the tail-flick test on delaying the short-term pain-relieving effect after administering the H. erinaceus alcohol extraction mixture or alcohol extract according to Item 1 in Embodiment 7.
- FIG. 9 shows the comparisons between groups in the tail-flick test on delaying the short-term pain-relieving effect before/after administering the H. erinaceus alcohol extraction mixture or alcohol extract according to Item 2 in Embodiment 7.
- FIG. 10 shows the comparisons of the maximum possible effect calculated from the differences in the tail-flick test on delaying the short-term pain-relieving effect before/after administering the H. erinaceus alcohol extraction mixture or alcohol extract according to Item 3 in Embodiment 7.
- FIG. 11 shows the comparisons between groups in the hot-plate test on delaying the long-term pain-relieving effect after administering the H. erinaceus alcohol extraction mixture or alcohol extract according to Item 4 in Embodiment 7.
- the purpose of the present invention is to provide a preparation method to prepare the miscellaneous types of active substances from H. erinaceus . Furthermore, novel heripene compounds are isolated and purified, and the heripenes and the active substances can further be prepared as a pharmaceutical composition with the pain-relieving effect.
- the cellular model for P2R is established to detect the P2R's functions.
- the P2R expression in the cell line is detected by the reverse transcription-polymerase chain reaction (RT-PCR).
- the receptor's functions are detected by the stimulation of the stimulator.
- the intracellular free calcium-ion concentration is used as the detection target of the receptor's functions because P2XR and P2YR can both be correlated with calcium-ion signaling.
- nociception can be generated in the central nervous system by the P2R transmission, it still needs to be confirmed via animal behavior.
- the pain-relieving effect of the active substances in the present invention can be identified by determining the generation of pain.
- the level of nociception in live animals is determined by two behavioral experiments, the tail flick test and the hot-plate test.
- the potential analgesic active components are prepared from the naturally edible mushroom, analyzed via the nociception mechanism and the experiments on animals' behavior, and further prepared as a pharmaceutical composition including the erinacine S or the active substances.
- the species, Hericium erinaceus , used in the embodiments of the present invention has been deposited in the China General Microbiological Culture Collection Center (CGMCC), Beijing, China with the Deposit No. CGMCC 10905. Originally, this species was purchased from the Bioresource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute, Taiwan, with the Accession No. BCRC 35669. However, the active substances of H. erinaceus described in the present invention are not limited to one from which this species is obtained.
- the liquid culture of the H. erinaceus mycelia is described as follows.
- the mycelium of H. erinaceus was inoculated on an agar plate to incubate at an adequate temperature of 15-32° C. for about 14 days.
- the mycelium was inoculated into a medium (where the ingredients are listed below) in a flask, and incubated to the early log phase with shakes at 20-30° C., pH 4.5-6.5 at the shaking rate of 100-250 rounds per minute (rpm) for 3-5 days.
- the culture in the flask was inoculated into the medium (which has the same ingredients as in the flask) of the fermentation tank, and cultured at 24-32° C., a tank pressure of 0.8-1.2 kg/cm 2 , a pH value of about 4.5-5.5, an aeration rate of a gas of 0.5-1 volume per volume per minute (vvm) and a stirring rate of 10-150 rpm for 8-16 days to obtain a fermentation medium of H. erinaceus mycelia including the mycelia and the supernatant, where the gas is air, a mixture of air, oxygen, carbon dioxide or nitrogen, and the preferred gas is air.
- the complex carbon and nitrogen source may be grain (e.g. wheat powder or wheat bran) or legume (e.g. soybean flour, mung bean flour and so on), the inorganic salt may be magnesium sulfate, potassium hydrogen phosphate, potassium dihydrogen phosphate, ferric sulfate, zinc sulfate and so on, the saccharide may be glucose, fructose, maltose, sucrose and so on, and the remainder is water in addition to the ingredients above.
- grain e.g. wheat powder or wheat bran
- legume e.g. soybean flour, mung bean flour and so on
- the inorganic salt may be magnesium sulfate, potassium hydrogen phosphate, potassium dihydrogen phosphate, ferric sulfate, zinc sulfate and so on
- the saccharide may be glucose, fructose, maltose, sucrose and so on, and the remainder is water in addition to the ingredients above.
- a defoaming agent may be additionally supplemented into the medium in the fermentation tank to prevent the generation of too much foam during the cultivation, and may be commercially common ones, such as a 0.01% water-based defoaming agent including silicon oil and silicones.
- the cultivation method in the embodiment is described below in detail.
- % digitonin was added to enable the cells to become transparent, and the maximum fluorescence ratio (Rmax) was obtained at a concentration of 2 mM Ca 2+ .
- Ethyleneglycol bis(2-aminoethylether)tetraacetic acid (EGTA) then was added to chelate with the calcium ions to obtain a minimum fluorescence ratio (Rmin).
- the dissociation coefficient (Kd) of fura-2 to Ca 2+ is 225 nM.
- the intracellular calcium-ion concentration was calculated using formulas (Grynkiewicz et al., J. Biol. Chem. 1985. 260(6):3440-3450).
- the tail flick test (also called the thermosensitive tail-flicking assay) (Fukui et a., Eur. J. Pharmacol. 2001. 419(1):25-31; Okada et al., J. Pharmacol. Exp. Ther. 2002. 303(1):66-73) is mainly used to measure the threshold of nociception when a mouse's tail is stimulated by infrared radiation. During the experiment, mice were not anesthetized, and the mouse tail (1 to 2 cm away from the end) was disposed on a specific groove of a heating panel.
- the infrared radiation heater from an infrared light source calibrator was turned on, and the emitted infrared concentrated on the mouse tail via a paraboloid reflector.
- the experimental animal felt pain, its tail gently flicked the panel, and thus this reaction is called the tail flick test.
- the built-in sensor detected this reaction and recorded the tail-flick reaction time.
- the threshold of nociception may be expressed as the seconds of the tail flick, also may be expressed as the variation of seconds before/after administration. Even the variation of the seconds of tail flick can be further calculated as a maximum possible effect (MPE).
- the heater was first pre-heated to a specific temperature, and then the experimental animal was subjected to the heat stimulation from the metal plate of the heater.
- the reaction that the experimental animal felt pain and jumped due to heat is called the paw withdrawal reaction.
- the required time that each experimental animal jumps after being disposed on the heater is called the paw withdrawal reaction time.
- the paw withdrawal reaction time refers to the threshold of nociception for the experimental animal.
- the H. erinaceus mycelium was inoculated on a potato dextrose agar (PDA) plate and incubated at 25° C. for about 7 days.
- PDA potato dextrose agar
- the H. erinaceus mycelium was aseptically scraped from the agar plate above to inoculate into the medium (see below) in the flask, followed by the shaking incubation in the orbital incubator at a shaking rate of 120 rounds per minute (rpm), at about 26° C., pH 5.0 for 5 days.
- the medium used in the fermentation tank is the same as the incubation step for the flask.
- the incubated mycelia in the flask were inoculated into the medium in the fermentation tank.
- the fermented medium containing the mycelia, the supernatant and the active substances having the pain-relieving effect was obtained after 12 days.
- the fermented medium was freeze-dried to obtain freeze-dried powder of the H. erinaceus mycelia (abbreviated as “the freeze-dried powder”).
- a 20-metric ton fermented medium was freeze-dried to obtain about 80 kg freeze-dried powder.
- the freeze-dried powder of the H. erinaceus mycelia was added to a 95 v/v % ethanol solution (1:25 w/w) to perform a first extraction, followed by the ultra-sonication at a sonication rate of 120 rpm for 1 hour.
- the suspension was centrifuged to obtain the supernatant.
- a second extraction was performed on the supernatant using 85 v/v % ethanol solution, and the ultra-sonication and centrifugation steps above were repeated to obtain a supernatant.
- the supernatant was concentrated under reduced pressure to obtain a cream of the H. erinaceus mycelia alcohol extract (hereinafter abbreviated as “the alcohol extract”).
- the freeze-dried powder and an equal amount of the alcohol extract were mixed, and then centrifuged to obtain the supernatant.
- the supernatant was freeze-dried to obtain a mixture of the H. erinaceus mycelia and the alcohol extract (hereinafter abbreviated as “the alcohol extraction mixture”).
- the preparation method for the erinacine S standard is described as follows.
- the erinacine S was obtained using a reverse chromatography column Cosmosil 5C18-AR-II (Nacalai USA, California, U.S.A.) at 40° C.
- the retention time of the erinacine S is 14 minutes.
- the HPLC analytic result is shown in FIG. 1 (where the label is the erinacine S standard).
- the upper curve indicates the freeze-dried powder of the H. erinaceus mycelia alcohol extract
- the lower curve indicates the erinacine S standard.
- the erinacine S standard is a standard prepared using the method above by the Applicant, and acts as a quantification basis for the erinacine S in the components of the extract.
- the chromatography plot of the prepared alcohol extract in Embodiment 2 shows that peaks appear at the retention times of 2, 7 and 14 minutes. Comparing the erinacine S standard with the one peak at 14 minutes, it can be determined that the peak indicates erinacine S.
- the erinacine S in the alcohol extract is quantified as 59 ppm.
- PC12 Three cell lines, i.e. rat pheochromocytoma cell line PC12, human neuroblastoma cell line SH-SY5Y and human osteosarcoma cell line HOS, were used.
- PC12 cells were incubated in a Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) horse serum (HS) and 5% (v/v) fetal bovine serum (FBS) (Kao et al., Toxicol. Sci., 2012, 125(2):462-472).
- DMEM Dulbecco's Modified Eagle Medium
- FBS fetal bovine serum
- Human neuroblastoma SH-SY5Y cells were incubated in a DMEM/F-12 medium supplemented with 10% (v/v) FBS (Liu et al., J.
- HOS cells were incubated in a minimum essential medium (MEM) (containing Earle's salts, 2 mM L-glutamine and 0.1 mM non-essential amino acids) supplemented with 1.5 g/L sodium bicarbonate and 1 mM pyruvate sodium, and an extra 5% (v/v) FBS was added during use.
- MEM minimum essential medium
- Cells were grown in a 5% CO 2 humidified incubator at 37° C. The medium was replaced every 2-3 days, and cells were sub-cultured using trypsin-ethylenediaminetetraacetic acid (EDTA) (Liu et al., Eur. J. Pharmacol., 2011, 650(1):34-40).
- EDTA trypsin-ethylenediaminetetraacetic acid
- RNA samples were washed with phosphate buffered saline (PBS), and mRNA was obtained in the column using a NucleoSpin® RNA II kit (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany), and the concentration of RNA was determined using an ACTGene ASP-2680 spectrophotometer (CellTAGen, Seoul, Republic of Korea).
- ACTGene ASP-2680 spectrophotometer
- RT-PCR reverse transcriptase-polymerase chain reaction
- mRNA was reverse-transcribed as cDNA, and then PCR was performed on this cDNA using a Q-AmpTM 2 ⁇ HotStart PCR master mix (containing Taq DNA polymerase) (Bio-Genesis Technologies, Inc., Taiwan) and the P2R primers.
- the obtained PCR product was electrophoresed in 1.5% (w/v) agarose gel in the buffer (containing 0.5 ⁇ Tris-borate EDTA (TBE)) in an electrophoresis tank.
- the voltage during the electrophoresis was set at 50 V, and the voltage was increased to 100 V for 15 minutes.
- the agarose gel was stained with ethidium bromide (EtBr), and then was transferred to a gel image system to be illuminated by ultraviolet (UV) radiation. The gel image was recorded, and the P2R expressed by the cells was observed.
- EtBr ethidium bromide
- FIGS. 2(A), 2(C) and 2(E) show the mRNA expressions of the P2X subtype receptors
- FIGS. 2(B), 2(D) and 2(F) show the mRNA expressions of the P2Y subtype receptors
- HOS, SH-SY5Y or PC12 in the lower left corner in each panel is the cell line's name. It can be seen that the P2XR subtypes (i.e.
- P2X 1 R, P2X 4 R, P2X 5 R, P2X 6 R and P2X 7 R) and the P2YR subtypes i.e. P2Y 1 R, P2Y 2 R, P2Y 4 R, P2Y 6 R and P2Y 11 R
- the P2XR subtypes i.e. P2X 3 R, P2X 4 R, P2X 5 R, P2X 6 R and P2X 7 R
- P2YR subtypes i.e.
- P2Y 1 R, P2Y 2 R, P2Y 4 R and P2Y 11 R were detected in the human neuroblastoma cell line SH-SY5Y, and the P2XR subtypes (i.e. P2X 2 R, P2X 3 R and P2X 4 R) and the P2YR subtype (i.e. P2Y 12 R) were detected in the rat neuronal cell line PC12.
- FIGS. 3(A), 3(B) and 3(C) show the variations of the calcium signals of the receptors in (A) human osteosarcoma HOS cells, (B) rat pheochromocytoma PC12 cells and (C) human neuroblastoma SH-SY5Y cells after being stimulated with 0.1 mM ATP.
- the intracellular free calcium-ion concentration in human neuroblastoma SH-SY5Y cells did not vary.
- the acetylcholine receptor on the human neuroblastoma SH-SY5Y cells was further stimulated with 0.1 mM carbachol to confirm that the cells do have molecules which are correlated to calcium-ion signals, and the results are shown in FIG. 3(C) .
- human osteosarcoma HOS cells were selected as the sample to further detect the P2R subtypes which may be correlated with calcium signals in human osteosarcoma HOS cells.
- the P2Y receptor is correlated with the G-protein (Gq).
- Gq can be activated after stimulating the receptor, to further activate phospholipase C so as to generate inositol 1,4,5-trisphosphate (IP3) and release calcium ions from the IP3-sensitive calcium pool in the cell. Therefore, the remaining calcium ions in the buffer in the experiment can be chelated when using a calcium ion-free buffer supplemented with an adequate amount of EGTA, so that no extracellular calcium ions can flow into the cells. On this condition, the intracellular free calcium-ion concentration was determined to indicate that the calcium ions are released from the calcium pool in the cell.
- FIGS. 5(A) and 5(B) show the calcium signals correlated with the P2Y receptor, wherein FIG.
- FIG. 5(A) shows that the calcium signals are induced by using ATP to stimulate the P2R in a calcium ion free buffer, and this is a response for the P2R receptor-correlated calcium signals because no extracellular calcium ions flow into the cells; and
- FIG. 5(B) shows the calcium signals induced using the uridine triphosphate (UTP) to stimulate cells. It is shown in FIGS. 5(A) and 5(B) that at least the P2Y 2 R- and P2Y 4 R-correlated calcium signals can be detected in human osteosarcoma HOS cells.
- ATP is a stimulator for P2R in the body, and thus 0.1 mM ATP is used to stimulate the P2R receptor.
- the H. erinaceus alcohol extract was added before the calcium signals were induced using ATP to stimulate the P2R. A secondary signal is equivalent to a physiological reaction after a receptor is stimulated. Therefore, it can be seen in FIG. 6 that the P2R's calcium signals induced by ATP are completed inhibited, and it is proved that P2R's functions can be inhibited by the H. erinaceus alcohol extract. It is proved in the above experiments that there are a variety of P2XRs and P2YRs on the HOS cells and the functions of the P2R receptors can be completely inhibited by the H.
- H. erinaceus alcohol extract and it is determined that the H. erinaceus alcohol extract has an inhibition effect on receptors such as P2X 1 , P2X 4 , P2X 5 , P2Y 7 , P2Y 2 , P2Y 4 receptors and so on.
- FIGS. 7(A) and 7(B) show the inhibition effect of (A) the H. erinaceus alcohol extract of 2.5, 5 and 50 ⁇ g/ml and (B) the erinacine S of 5, 10 and 15 ⁇ g/ml on the variation of the intracellular calcium-ion concentration in human osteosarcoma HOS cells induced using the ATP to stimulate the P2R receptor, and the inhibition effect is more significant in a dosage-dependent manner, indicating that the dosage given is correlated with the inhibition effect.
- This embodiment was performed to observe the mice's pain reaction to the extrinsic stimulation before/after administration via the tail flick test and the hot-plate test, after the mice were administered with the H. erinaceus active substances (i.e. the alcohol extract obtained in Embodiment 2 and the alcohol extraction mixture obtained in Embodiment 3) for a short term or a long term.
- H. erinaceus active substances i.e. the alcohol extract obtained in Embodiment 2 and the alcohol extraction mixture obtained in Embodiment 3
- mice in this experiment were divided into three groups, i.e. the control group, the H. erinaceus mycelia/alcohol extract (the alcohol extraction mixture group), and the H. erinaceus alcohol extract (the alcohol extract group).
- Each group had five male C57BL/6 Narl mice which were older than eight weeks old.
- the mice were orally administered with 2500 mg/kg of drugs via a soft feeding tube, and the mice in the control group were fed with an equal amount of water.
- the mouse's nociception was determined by the tail flick test before administration, and 30 and 60 minutes after administration.
- the experimental results were expressed as mean ⁇ standard deviation, and the significance of statistics among the alcohol extraction mixture group, the alcohol extract group and the control group was analyzed using Student's t-test. Therefore, the pain-relieving effect of administering the active substances for a short term can be observed, and the results are shown in FIG. 8 .
- the tail-flick basic values were examined before administration, the tail-flick reaction time in three groups was 4.1 ⁇ 1.5 seconds (s) in the control group, 4.3 ⁇ 1.9 s in the alcohol extraction mixture group, and 4.5 ⁇ 1.2 s in the alcohol extract group.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.8
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.6
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.8, indicating that there was no significant difference between groups before administration.
- the mouse's nociception reaction was determined by the tail flick test 30 minutes after administration.
- the experimental results show that the tail flick reaction time was 2.0 ⁇ 0.5 s in the control group, 6.2 ⁇ 1.6 s in the alcohol extraction mixture group, and 8.4 ⁇ 1.1 s in the alcohol extract group.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.0008 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.000009 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.07 without a significant difference.
- the mouse's nociception reaction was determined by the tail flick test 60 minutes after administration.
- the experimental results showed that the tail-flick reaction time was 2.1 ⁇ 0.57 s in the control group, 5.7 ⁇ 2.46 s in the alcohol extraction mixture group, and 7.2 ⁇ 1.9 s in the alcohol extract group.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.0256 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.0016 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.33 without a significant difference.
- the experimental conditions are similar to the condition in the subsection “1.
- the tail flick test after the H. erinaceus active substances was administered for a short term”, and the difference of the tail-flick reaction times among the alcohol extract group, the alcohol extraction mixture group and the control group was compared. Therefore, the pain-relieving effect of administering the active substances for a short term can be observed, and the results are shown in FIG. 9 .
- the mouse's nociception reaction was determined by the tail flick test 30 minutes after administration.
- the experimental results show that the tail-flick reaction time in the control group was shorter compared to the tail-flick basic value before administration, with a difference of ⁇ 2.1 ⁇ 1.7 s; the tail-flick reaction time in the alcohol extraction mixture group was longer compared to that before administration, with a difference of 2.6 ⁇ 2.18 s; and the tail-flick reaction time in the alcohol extract group was longer compared to that before administration, with a difference of 3.9 ⁇ 1.61 s.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.008 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.00108 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.35 without a significant difference.
- the mouse's nociception reaction was determined by the tail flick test 60 minutes after administration.
- the experimental results show that the tail-flick reaction time in the control group was shorter compared to the tail-flick basic value before administration, with a difference of ⁇ 1.0 ⁇ 0.71 s; the tail-flick reaction time in the alcohol extraction mixture group was longer compared to that before administration, with a difference of 2.0 ⁇ 2.53 s; and the tail-flick reaction time in the alcohol extract group was longer compared to that before administration, with a difference of 2.6 ⁇ 1.77 s.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.033 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.0028 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.66 without a significant difference.
- the conditions of this experiment are similar to those in the subsection “1.
- the tail flick test after the H. erinaceus active substances was administered for a short term” above, and the maximum possible effects (MPE) are calculated as follows.
- the tail-flick reaction time after administration minus the tail-flick reaction time before administration (a tail-flick basic value for a single mouse) have a difference, and then the difference divided by the tail-flick basic value for this single mouse is the MPE. Therefore, the pain-relieving effect of administering the active substances for a short term can be observed, and the results are shown in FIG. 10 .
- the mouse's nociception reaction was determined by the tail flick test 30 minutes after administration.
- the experimental results show that the tail-flick reaction time in the control group was shorter (about half) compared to the tail-flick basic value before administration; the tail-flick reaction time in the alcohol extraction mixture group was longer compared to that before administration; and the tail-flick reaction time in the alcohol extract group was longer by about one time compared to that before administration.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.03 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.0134 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.31 without a significant difference.
- the mouse's nociception reaction was determined by the tail flick test 60 minutes after administration.
- the experimental results show that the tail-flick reaction time in the control group was shorter compared to the tail-flick basic value before administration; the tail-flick reaction time in the alcohol extraction mixture group was longer by about one time compared to that before administration; and the tail-flick reaction time in the alcohol extract group was longer compared to that before administration.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.05 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.004 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.61 without a significant difference. It is predicted that the H. erinaceus active substances have an immediate pain-relieving effect which can at least continue for about 60 minutes.
- This assay is used to determine whether the administration of the H. erinaceus active substances for a long term can delay in response caused by the hot plate.
- Each mouse was fed with 2500 mg/kg active substance for three days, and the interval between two feeds was 24 hours.
- the hot-plate test was performed after feeding the active substances for three days, the amounts of paw lifting, licking or jumping were determined and the results are shown in FIG. 11 .
- the experimental results show that the paw withdrawal reaction time was 6.4 ⁇ 1.8 s in the control group, 11.7 ⁇ 2.5 s in the alcohol extraction mixture group, and was 11.5 ⁇ 1.8 s in the alcohol extract group.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.005 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.0025 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.09 without a significant difference.
- the paw withdrawal reaction time was determined again with the same experimental method.
- the experimental results show that the paw withdrawal reaction time was 6.3 ⁇ 0.8 s in the control group, 11.8 ⁇ 2.5 s in the alcohol extraction mixture group, and was 8.9 ⁇ 1.2 s in the alcohol extract group.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.007 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.010 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.09 without significant difference.
- the experimental results show that the paw withdrawal reaction time was 5.7 ⁇ 2.4 s in the control group, 11.7 ⁇ 2.3 s in the alcohol extraction mixture group, and was 10.3 ⁇ 2.0 s in the alcohol extract group.
- the p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.00006 with a significant difference
- the p-value for Student's t-test between the alcohol extract group and the control group was 0.0003 with a significant difference
- the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.81 without a significant difference.
- the alcohol extraction mixture and the alcohol extract have significant pain-relieving effects on a short-term reaction after a 30-minute administration, and the pain-relieving effect tended to decline after a 60-minute administration.
- deallergization occurs and the pain-relieving effect tends to stabilize.
- the H. erinaceus active substances including the H. erinaceus mycelia, the H. erinaceus alcohol extract, the H. erinaceus alcohol extraction mixture and the erinacine S disclosed in the present invention have been proven to have the pain-relieving effect, and can be widely used for pain relief.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Environmental Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention is related to an active substance of Hericium erinaceus having a pain-relieving effect, and a pharmaceutical composition including the active substance. The active substance is prepared using the following steps: (a) inoculating a mycelium of H. erinaceus on an agar plate and incubating at 15-32° C. for 8-16 days; (b) inoculating the incubated H. erinaceus mycelia from step (a) into a medium in a flask and incubating at 20-30° C. and pH 4.5-6.5 for 3-5 days; (c) inoculating the incubated H. erinaceus mycelia from step (b) into a medium in a fermentation tank and incubating at 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the H. erinaceus mycelia; and (d) desiccating the fermented medium of the H. erinaceus mycelia from step (c) to obtain the powder of the H. erinaceus mycelia, which is further purified and isolated to obtain a novel compound of H. erinaceus.
Description
- The present invention is related to an active substance with a pain-relieving effect, in particular, an active substance originated from Hericium erinaceus.
- The neural transduction pathway of nociception and the P2-purinoceptor (P2R)
- The generation of nociception involves the transduction of pain signals on a series of neural pathways, finally arriving at the cerebrum, so that a human body feels pain. The neural transduction pathway of nociception starts from the generation of stimulation, followed by transforming this stimulation into neurosignals by nociceptors. The neurosignals are transmitted to the dorsal root ganglion (DRG), followed by transmission to the spinal cord and finally arrive at the nociception area in the thalamus of the cerebrum. In the preceding research, it is indicated that the distribution of the P2-purinoceptors (P2Rs) can be seen on a series of neural transduction pathways, e.g. the sensory nerves, the sympathetic nerves, the parasympathetic nerves and the central nervous system, wherein the P2Rs on the sensory nerves are mainly the P2X3 receptor (P2X3R) and the P2X2/3 receptor (P2X2/3R).
- The literature with regard to the P2Rs and the neural transduction pathway of nociception is listed below.
- 1. The model of the gene knockout in mice proves that the P2X3R, P2X4 receptor (P2X4R) and P2X7 receptor (P2X7R) are related to the nociceptor, pain transmission, inflammatory pain and neuropathic pain (Collier et al., Nature, 1966, 212(5060):411-412; Cockayne et at, Nature, 2000, 407(6807):1011-1015; Souslova et al., Nature, 2000, 407(6807):1015-1017; Jarvis and Burgard, Br. J. Pharmacol., 2002, 135(6):1343-1344; Tsuda et al., Nature, 2003, 424(6950):778-783; Khakh and North, Nature, 2006, 442(7102):527-532; Burnstock, Nat. Rev. Drug Discov., 2008, 7(7):575-590; Beggs et at, Nat. Neurosci., 2012, 15(8):1068-1073).
- 2. The ATP of the P2X3R gene knockout mice does not induce the neural electrical signal transduction on the DRG, and does block the peripheral nociception which is transmitted to the central nervous system (Cockayne et al., Nature, 2000, 407(6807): 1011-1015).
- 3. The extent of the formalin-induced inflammatory pain is attenuated after deleting the P2X3R (Souslova et al., Nature, 2000, 407(6807):1015-1017).
- 4. The P2X3R antagonist can block the immediate pain, the inflammatory pain, and the visceral pain related to the neuropathic pain (Jarvis and Burgard, Br. J. Pharmacol., 2002, 135(6):1343-1344).
- 5. The expression of P2X4R increases sharply in the mice after a nerve injury, resulting in long-term pain-hypersensitivity (Tsuda et al., Nature, 2003, 424(6950):778-783).
- 6. It is found in the P2X4R knockout mice that the mice do not show the pain-hypersensitivity induced by the physical damage and lack the neural signaling pathways transmitted to the spinal cord because of a peripheral nerve injury (Ulmann et al., J. Neurosci. 2008. 28(44):11263-11268).
- 7. It is found that there is almost no inflammatory and neuropathic pain-hypersensitivity in the P2X7R knockout mice (Chessell et al., Pain, 2005, 114(3):386-396).
- 8. The P2X7R antagonist has the effect of reducing the neuropathic pain and the inflammatory pain (Honore, et al., J. Pharmacol. Exp. Ther., 2006, 319(3): 1376-1385).
- P2R
- P2R, based on its conformation and the signal transduction pathway, can be classified into two subfamilies, P2X1-P2X7 (P2X1-7) receptors and P2Y1-P2Y14 (P2Y1-14) receptors (Yang and Liang, Circ. Res., 2012, 111(4):397-401). Each of the P2X1-P2X7 receptors has two transmembrane domains, and its C- and N-terminal regions are within the cell. In addition, there is a loop-shaped protein structure outside the cell. Among the P2X1-P2X7 receptors, the smallest one, P2X4R, has 388 amino acids, and the largest one, P2X7R, has 595 amino acids. The P2X receptor (P2XR) is a cationic channel receptor, allowing Na+ and Ca2+ to pass through. After the P2X receptor is stimulated, Ca2+ flows into the cells through the P2XR, so as to increase the intracellular free calcium-ion concentration ([Ca2+]c↑), which acts as a secondary signal to induce the subsequent physiological reactions. The neurosignals are sent to the thalamus of the cerebrum via the spinal cord to generate the nociception. At the same time, the increased intracellular free calcium-ion concentration ([Ca2+]c↑) further influences the cellular secretion. Concretely speaking, it may stimulate neuroimmunological cells to secrete cytokines. On the other hand, the P2Y1-14 receptors are G-protein coupled receptors (GPCR). In addition to the P2Y11-14 receptors, other P2Y subtypes are correlated to the G-protein (Gq). After actuation, Gq activates phospholipase C-β (PLC-β) to cleave the
phosphatidylinositol 4,5-bisphosphate (PIP2) to generateinositol - Adenosine triphosphate (ATP)
- ATP is a well-known energy-carrying and energy-transferring biomolecule. Szent-Gyorgyi found in 1929 that the ATP also has extracellular biological functions (Drury and Szent-Györgyi, J. Physiol., 1929, 68(3):213-237). In 1996, ATP was formally deemed as a neurotransmitter in the neuroscience field. ATP acts as a neurotransmitter for P2R on the P2R-related neuronal signaling pathways. When the nerves are stimulated, ATP releases from the synaptic vesicles to the synaptic cleft and stimulates the P2R on the neuron behind the synapse. Subsequently, ATP is quickly decomposed by enzymes in the synaptic cleft. The neurotransmission model above is also supported by the published literature as in the following examples.
- 1. ATP mediates the signaling transmission at the presynaptic and the postsynaptic neurons, and plays a role in the neurotransmitter (Burnstock, Trends Pharmacol. Sci., 2006, 27(3):166-176; Burnstock, Nat. Rev. Drug Discov., 2008, 7(7):575-590).
- 2. ATP is released after tissue injury, and stimulates the P2R-mediated nociception on the pain receptor.
- 3. It is found that ATP may stimulate the P2R mediator on the human skin to induce the nociception (Collier et al., Nature, 1966, 212(5060): 411-412).
- 4. ATP plays an important role in the transmission of nociception (Burnstock, Pharmacol. Ther., 2006, 110(3):433-454; Burnstock, Keio. J. Med., 2013, 62(3):63-73).
- The Need for Analgesics
- The analgesic market tends to become larger along with the aging population in society and gradual improvement to the requirements of quality of life. Among the various types of pain, the ones that are hard to treat are neuropathy-induced neuropathic pain and cancer pain. One reason is that there are few efficient drugs that thoroughly inhibit pain. Further, the relief of this long-term pain requires analgesics for long-term use. There are two main types of clinical analgesics, one is morphine analgesics, and the other is non-narcotic analgesics. If patients are administered with a morphine analgesic for a long time, this could cause tolerance and dependence problems. Tolerance means that the efficiency of a drug will gradually attenuate along with an increase of the given dosage, and it is necessary to increase the given dosage to achieve the analgesic effect. Non-narcotic analgesics do not have adverse reactions (such as respiratory depression, habituation and so on) similar to narcotics, but have analgesic and anti-inflammatory functions and can decrease the rising body temperature (antipyretic function) to attenuate the inflammatory symptoms. These drugs are usually used to relieve the mild-to-moderate pain caused by diseases such as rheumatism, arthritis, ischialgia, degenerative arthritis and so on. These drugs are also the nonsteroidal anti-inflammatory drugs (NSAIDs) with the side effects of the simultaneous inhibition of cyclooxygenase-1 (COX-1) and COX-2. When COX-2 is inhibited, the expression of prostaglandin 12 (PGI2) is decreased which results in the anti-inflammatory and analgesic functions and promotes the aggregation of blood platelets. When COX-1 is inhibited, the mucosal integrity of the gastrointestinal tract is destroyed and the renal blood flow is influenced. This results in side effects such as stomach injury, kidney injury and so on, and inhibits the platelet aggregation which results in frequent bleeding. Therefore, analgesics' safety, side effects, addiction and sensitivity to tolerance are all problems to be solved, so as to develop a more excellent analgesic agent.
- Hericium erinaceus
- The anesthesiologist Allen W. Burton stated, “New analgesics still cannot satisfy the demands of clinical oncology, and we frequently feel helpless to many intractable analgesic patients.” (Burton et al., Pain Med., 2007, 8(2):189-198) Therefore, it is very important and urgently essential for the current clinical medicine to develop a safe and efficient analgesic against new biological pathways. Accordingly, starting from the consideration of safety, it is the current trend in industries to search for any active substances from natural edible materials and prepare the active substances as long-term drugs.
- According to the description in Medicinal Fungi of China, “H. erinaceus tastes sweet, is neutral and tonic, has benefits for five viscera and digestion, and has excellent effects on dyspepsia, neurodegeneration, duodenal ulcer and gastric ulcer” (Mao, X.-L. Chinese edible and pharmaceutical large fungi. Microbiology China, 1989. 16(5):290-297). Therefore, it is known that H. erinaceus, a pharmaceutical and edible fungi, has an effect of disease treatment in ancient medicine. H. erinaceus is classified in the kingdom Fungi, the phylum Eumycota, the subphylum Basidiomycotina, the class Basidiomycetes, the order Aphyllophorales, the family Hydnaceae, the subfamily Hericioideae, and the genus Hericium. H. erinaceus's fruiting body has a soft and spherical appearance with many bars with rough protuberances. H. erinaceus is white when fresh and turns tawny after being dried. The H. erinaceus fruiting body or mycelia extract contains saccharides (Wang et al., Kaohsiung J. Med. Sci., 2001, 17(9):461-467; Yang et al., Biosci. Biotechnol. Biochem., 2003, 67(6):1292-1298), erinacines (Saito et al., J. Antibiot., 1998, 51(11):983-990; Kenmoku et al., Biosci. Biotechnol. Biochem., 2002, 66(3):571-575; Kenmoku et al., Biosci. Biotechnol. Biochem., 2004, 68(8):1786-1789; Watanabe et al., Org. Lett., 2007, 9(2):359-362; Watanabe and Nakada, J. Am. Chem. Soc., 2008, 130(4):1150-1151; Lee et al., Int. J. Mol. Sci., 2014, 15(9):15073-15089; Li et al., Food Chem. Toxicol., 2014, 70:61-67), dilinoleoyl-phosphatidylethanolamine (DLPE) (Nagai et al., J. Nutr. Biochem., 2006, 17(8):525-530), amino acids, proteins, and minor elements (Jia et al., Carbohydr. Res., 2004, 339(16):2667-2671). In the literature, it is common knowledge that polysaccharides of H. erinaceus have effects on immunoregulation, blood lipid reduction, blood sugar reduction, the inhibition of gastric inflammation, or the occurrence of stomach cancer. So far, Japanese scientists have isolated and purified 14 erinacines, i.e. erinacines A, B, C, D, E, F, G, H, I, J, K, P, Q and R, from a submerged fermentation product. Erinacines can stimulate astrocytes in mice to secrete the neuron growth factors (NGF), so as to remedy diseases such as intellectual deterioration, neurodegeneration and so on. The inventors isolated, purified and identified novel compounds, i.e. heripenes, from the alcohol extract of the H. erinaceus mycelia, and proved in the experimental result that heripenes have the analgesia effect. The detail is described as follows.
- The purpose of the present invention is to disclose the heripene and a preparation method for an active substance of H. erinaceus, and the preparation is used to prepare the heripene, the active substance and a pharmaceutical composition containing the heripene or the active substance for a pain-relieving effect.
- To achieve this purpose, the present invention discloses a preparation method for an active substance of H. erinaceus having an effect of relieving a pain, including the following steps of:
- (a) inoculating a mycelium of the H. erinaceus on an agar plate and incubating at a temperature of 15-32° C. for 8-16 days;
- (b) inoculating the incubated mycelium of the H. erinaceus from step (a) into a medium in a flask and incubating at a temperature of 20-30° C. and pH 4.5-6.5 for 3-5 days;
- (c) inoculating the incubated mycelium of the H. erinaceus from step (b) into a medium in a fermentation tank and incubating at a temperature of 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the mycelium of the H. erinaceus; and
- (d) desiccating the fermented medium of the mycelium of the H. erinaceus from step (c) to obtain a powder of the mycelium of the H. erinaceus.
- Preferably, an incubation in step (b) is a shaking incubation at a shaking rate of 100-250 rounds per minute (rpm).
- Preferably, the fermentation tank in step (c) has a tank pressure of 0.8-1.2 kg/cm2 and a stirring rate of 10-150 rpm, and a gas is introduced into the fermentation tank at an aeration rate of 0.5-1 volume per volume per minute (vvm).
- Preferably, the gas is air, oxygen, carbon dioxide, nitrogen gas or a combination thereof.
- Preferably, the medium used in step (b) and the medium used in step (c) are the same.
- Preferably, the medium includes one or more combinations from a complex carbon and nitrogen source, animal or plant sources of protein or a hydrolyzate thereof, an inorganic salt, a saccharide, a yeast or a malt extract, and a defoaming agent.
- Preferably, the complex carbon and nitrogen source is a grain or a legume, and the inorganic salt is a sulfate or a phosphate.
- Preferably, the powder of the mycelium of the H. erinaceus from step (d) is further extracted with an alcohol solvent to obtain an alcohol extract of the mycelium of the H. erinaceus.
- Preferably, the alcohol solvent is an ethanol of 30-100 volume-volume percentage (v/v %) or a methanol of 30-100 v/v %.
- Preferably, the alcohol extract of the mycelium of the H. erinaceus is further extracted with a water and an ethyl acetate, followed by a column chromatography to obtain the heripene having a structural formula (I) as follows:
- where R is hydrogen, hydroxyl, C1-C10 alkyl, C1-C10 alkenyl or C1-C10 alkynyl, which are optionally substituted with a substitute containing halogen, oxygen, nitrogen, phosphorus or sulfur; where the stereocenters at C-5, C-6, C-9, C-13, C-14, C-21, C22 and C-23 are an R-configuration or an S configuration.
- The phrase “the functional group R being optionally substituted with a substituted” means that two functional groups R can be individually or both substituted with a substitute containing halogen, oxygen, nitrogen, phosphorus or sulfur.
- Preferably, when the group R of the heripene having the structural formula (I) is hydrogen, the heripene is the erinacine S having a structural formula (II) as follows:
- Preferably, a ratio of water to ethyl acetate is 1:4.
- Preferably, the pain for treatment in the preparation method above is a neuropathic pain or a cancer pain.
- Preferably, a signaling pathway for the pain in the preparation method above includes a P2-purinoceptor (P2R).
- The present invention further discloses an active substance of the H. erinaceus having an effect of reducing a pain and being prepared by any one of the preparation methods above.
- Preferably, the active substance of the H. erinaceus is powder after being prepared by the preparation method above.
- Preferably, the active substance of the H. erinaceus is an alcohol extract after being prepared by the preparation method above.
- Preferably, the active substance of the H. erinaceus is the heripene having a structural formula (I) after being prepared by the preparation method above.
- Preferably, the heripene is the erinacine S having the structural formula (II) when R of the heripene of the structural formula (I) is hydrogen.
- The present invention further discloses a heripene compound having a structural formula (I).
- Preferably, the heripene compound is the erinacine S having a structural formula (II) when R of the heripene compound of the structural formula (I) is hydrogen.
- Preferably, the heripene compound above has a pain-relieving effect.
- The present invention further discloses a pharmaceutical composition having a pain-relieving effect, including an active substance of the H. erinaceus above, and a biologically acceptable carrier, excipient, diluent or adjuvant.
- The present invention further discloses a pharmaceutical composition having a pain-relieving effect, including a heripene compound above, and a biologically acceptable carrier, excipient, diluent or adjuvant.
-
FIG. 1 illustrates an HPLC analytic spectrum of the erinacine S according toEmbodiment 4. -
FIGS. 2(A), 2(B), 2(C), 2(D), 2(E) and 2(F) show the gene expression of the P2R receptors in the cells, which are monitored using the RT-PCR according toItem 2 ofEmbodiment 5. -
FIGS. 3(A), 3(B) and 3(C) show the calcium signals of the receptor in the cells, which are monitored after cells are filled with a fluorescent agent according toItem 1 ofEmbodiment 6, wherein (A) human osteosarcoma HOS cells, (B) rat pheochromocytoma PC12 cells, and (C) human neuroblastoma SH-SY5Y cells are stimulated with ATP and then with carbachol. -
FIG. 4 shows the calcium signals correlated with the P2XR subtypes in human osteosarcoma HOS cells according toItem 2 inEmbodiment 2. -
FIGS. 5(A) and 5(B) show the calcium signals correlated with the P2YR subtypes in human osteosarcoma HOS cells according toItem 2 inEmbodiment 2, wherein (A) the calcium signals are induced by ATP stimulation in a calcium free buffer, and (B) the calcium signals are induced by uridine triphosphate (UTP) stimulation. -
FIG. 6 shows the effect of the H. erinaceus mycelia alcohol extract on the ATP-stimulated P2R's calcium signals in the human osteosarcoma HOS cells according toItem 3 inEmbodiment 6. -
FIGS. 7(A) and 7(B) show the inhibition effect of the calcium signals induced by (A) the alcohol extract and (B) the erinacine S treatments, followed by the ATP stimulation in the human osteosarcoma HOS cells according toItem 4 inEmbodiment 6. -
FIG. 8 shows the comparisons between groups in the tail-flick test on delaying the short-term pain-relieving effect after administering the H. erinaceus alcohol extraction mixture or alcohol extract according toItem 1 inEmbodiment 7. -
FIG. 9 shows the comparisons between groups in the tail-flick test on delaying the short-term pain-relieving effect before/after administering the H. erinaceus alcohol extraction mixture or alcohol extract according toItem 2 inEmbodiment 7. -
FIG. 10 shows the comparisons of the maximum possible effect calculated from the differences in the tail-flick test on delaying the short-term pain-relieving effect before/after administering the H. erinaceus alcohol extraction mixture or alcohol extract according toItem 3 inEmbodiment 7. -
FIG. 11 shows the comparisons between groups in the hot-plate test on delaying the long-term pain-relieving effect after administering the H. erinaceus alcohol extraction mixture or alcohol extract according toItem 4 inEmbodiment 7. - The purpose of the present invention is to provide a preparation method to prepare the miscellaneous types of active substances from H. erinaceus. Furthermore, novel heripene compounds are isolated and purified, and the heripenes and the active substances can further be prepared as a pharmaceutical composition with the pain-relieving effect.
- Principles of the Experiments
- The cellular model for P2R is established to detect the P2R's functions. At first, the P2R expression in the cell line is detected by the reverse transcription-polymerase chain reaction (RT-PCR). The receptor's functions are detected by the stimulation of the stimulator. The intracellular free calcium-ion concentration is used as the detection target of the receptor's functions because P2XR and P2YR can both be correlated with calcium-ion signaling. Although nociception can be generated in the central nervous system by the P2R transmission, it still needs to be confirmed via animal behavior. The pain-relieving effect of the active substances in the present invention can be identified by determining the generation of pain. Therefore, the level of nociception in live animals is determined by two behavioral experiments, the tail flick test and the hot-plate test. In the present invention, the potential analgesic active components are prepared from the naturally edible mushroom, analyzed via the nociception mechanism and the experiments on animals' behavior, and further prepared as a pharmaceutical composition including the erinacine S or the active substances.
- Experimental Method
- The Source of the Species:
- The species, Hericium erinaceus, used in the embodiments of the present invention has been deposited in the China General Microbiological Culture Collection Center (CGMCC), Beijing, China with the Deposit No. CGMCC 10905. Originally, this species was purchased from the Bioresource Collection and Research Center (BCRC) of the Food Industry Research and Development Institute, Taiwan, with the Accession No. BCRC 35669. However, the active substances of H. erinaceus described in the present invention are not limited to one from which this species is obtained.
- Submerged Cultivation:
- The liquid culture of the H. erinaceus mycelia is described as follows. The mycelium of H. erinaceus was inoculated on an agar plate to incubate at an adequate temperature of 15-32° C. for about 14 days. Subsequently, the mycelium was inoculated into a medium (where the ingredients are listed below) in a flask, and incubated to the early log phase with shakes at 20-30° C., pH 4.5-6.5 at the shaking rate of 100-250 rounds per minute (rpm) for 3-5 days. Finally, the culture in the flask was inoculated into the medium (which has the same ingredients as in the flask) of the fermentation tank, and cultured at 24-32° C., a tank pressure of 0.8-1.2 kg/cm2, a pH value of about 4.5-5.5, an aeration rate of a gas of 0.5-1 volume per volume per minute (vvm) and a stirring rate of 10-150 rpm for 8-16 days to obtain a fermentation medium of H. erinaceus mycelia including the mycelia and the supernatant, where the gas is air, a mixture of air, oxygen, carbon dioxide or nitrogen, and the preferred gas is air.
- The formula of the medium is listed as follows.
-
Ingredients Amount (wt. %) Complex carbon and nitrogen source 0.01-10 Animal or plant sources of protein or its hydrolyzate 0.01-5 Yeast or melt extract thereof (powder or cream) 0.001-2 Inorganic salt 0.0001-2 Saccharide 0.01-20 Defoaming agent 0.01-0.5 Water Add to 100 wt. % - The complex carbon and nitrogen source may be grain (e.g. wheat powder or wheat bran) or legume (e.g. soybean flour, mung bean flour and so on), the inorganic salt may be magnesium sulfate, potassium hydrogen phosphate, potassium dihydrogen phosphate, ferric sulfate, zinc sulfate and so on, the saccharide may be glucose, fructose, maltose, sucrose and so on, and the remainder is water in addition to the ingredients above.
- A defoaming agent may be additionally supplemented into the medium in the fermentation tank to prevent the generation of too much foam during the cultivation, and may be commercially common ones, such as a 0.01% water-based defoaming agent including silicon oil and silicones. The cultivation method in the embodiment is described below in detail.
- The Detection of Calcium Signals Using Fluorescence:
- Cells were filled with a fluorescent dye-based calcium indicator, “Fura-2, AM cell permeant” (ThermoFisher Scientific, Waltham, Mass., U.S.A.), and the variation of the fluorescence level at an emission wavelength of 505 nm was determined at two excitation wavelengths of 340 nm and 380 nm using a fluorescence spectrometer (SPEX® 1681, Spec Industries, Inc., New Jersey, U.S.A.). During the experiment, ATP was added to cells to stimulate the P2R expression, and the variation of the fluorescence level was observed. Finally, 1 wt. % digitonin was added to enable the cells to become transparent, and the maximum fluorescence ratio (Rmax) was obtained at a concentration of 2 mM Ca2+. Ethyleneglycol bis(2-aminoethylether)tetraacetic acid (EGTA) then was added to chelate with the calcium ions to obtain a minimum fluorescence ratio (Rmin). The dissociation coefficient (Kd) of fura-2 to Ca2+ is 225 nM. The intracellular calcium-ion concentration was calculated using formulas (Grynkiewicz et al., J. Biol. Chem. 1985. 260(6):3440-3450).
- Tail Flick Test:
- The tail flick test (also called the thermosensitive tail-flicking assay) (Fukui et a., Eur. J. Pharmacol. 2001. 419(1):25-31; Okada et al., J. Pharmacol. Exp. Ther. 2002. 303(1):66-73) is mainly used to measure the threshold of nociception when a mouse's tail is stimulated by infrared radiation. During the experiment, mice were not anesthetized, and the mouse tail (1 to 2 cm away from the end) was disposed on a specific groove of a heating panel. Next, the infrared radiation heater from an infrared light source calibrator was turned on, and the emitted infrared concentrated on the mouse tail via a paraboloid reflector. When the experimental animal felt pain, its tail gently flicked the panel, and thus this reaction is called the tail flick test. When the tail flick reaction occurred, the built-in sensor detected this reaction and recorded the tail-flick reaction time. The threshold of nociception may be expressed as the seconds of the tail flick, also may be expressed as the variation of seconds before/after administration. Even the variation of the seconds of tail flick can be further calculated as a maximum possible effect (MPE). The formula is: (% MPE)=(Postdrug latency−Predrug latency)/(Cutoff time−Predrug latency)×100%.
- Hot-Plate Test:
- In the mouse hot-plate test (Yaksh and Tyce, Brain Res. 1979. 171(1):176-181), the heater was first pre-heated to a specific temperature, and then the experimental animal was subjected to the heat stimulation from the metal plate of the heater. The reaction that the experimental animal felt pain and jumped due to heat is called the paw withdrawal reaction. The required time that each experimental animal jumps after being disposed on the heater is called the paw withdrawal reaction time. Finally, the paw withdrawal reaction time refers to the threshold of nociception for the experimental animal.
- The Incubation on the Agar Plate:
- The H. erinaceus mycelium was inoculated on a potato dextrose agar (PDA) plate and incubated at 25° C. for about 7 days.
- The Incubation in the Flask:
- The H. erinaceus mycelium was aseptically scraped from the agar plate above to inoculate into the medium (see below) in the flask, followed by the shaking incubation in the orbital incubator at a shaking rate of 120 rounds per minute (rpm), at about 26° C., pH 5.0 for 5 days.
- The formula of the medium is listed as follows.
-
Ingredients Amount (wt. %) Glucose 2.0 Yeast extract 0.1 Animal or plant sources of 0.1 protein and its hydrolyzate Magnesium sulfate 0.001 soybean flour 0.1 Water Add to 100 wt. % - The Incubation in the Fermentation Tank:
- The medium used in the fermentation tank is the same as the incubation step for the flask. The incubated mycelia in the flask were inoculated into the medium in the fermentation tank. At 26° C., a tank pressure of 0.5-1.0 kg/cm2, pH 5.0 and with or without (air lift) a stirring rate of 10-150 rpm, air was introduced at an aeration rate of 0.5-1 volume per volume per minute (vvm), and the inoculated mycelia were incubated for 12 days. The fermented medium containing the mycelia, the supernatant and the active substances having the pain-relieving effect was obtained after 12 days. The fermented medium was freeze-dried to obtain freeze-dried powder of the H. erinaceus mycelia (abbreviated as “the freeze-dried powder”). A 20-metric ton fermented medium was freeze-dried to obtain about 80 kg freeze-dried powder.
- The freeze-dried powder of the H. erinaceus mycelia was added to a 95 v/v % ethanol solution (1:25 w/w) to perform a first extraction, followed by the ultra-sonication at a sonication rate of 120 rpm for 1 hour. The suspension was centrifuged to obtain the supernatant. A second extraction was performed on the supernatant using 85 v/v % ethanol solution, and the ultra-sonication and centrifugation steps above were repeated to obtain a supernatant. Finally, the supernatant was concentrated under reduced pressure to obtain a cream of the H. erinaceus mycelia alcohol extract (hereinafter abbreviated as “the alcohol extract”).
- The freeze-dried powder and an equal amount of the alcohol extract were mixed, and then centrifuged to obtain the supernatant. The supernatant was freeze-dried to obtain a mixture of the H. erinaceus mycelia and the alcohol extract (hereinafter abbreviated as “the alcohol extraction mixture”).
- The preparation method for the erinacine S standard is described as follows. The H. erinaceus mycelia alcohol extract was subjected to liquid-liquid partition (H2O:ethyl acetate (EA)=1:4 (v/v)), and the obtained ethyl acetate extract was further subjected to column chromatography on silica gel and Sephadex® LH-20 silica gel, followed by the gradient elution of n-hexane:EA (10:1, 3:1, 3:2, 1:1, 1:2, 0:1; v/v), to obtain 7 sub-partitions. The sub-partition 3 (which was eluted with n-hexane:EA=3:2 (v/v)) was further subjected to column chromatography on the Sephadex LH-20 silica gel to obtain a new compound, erinacine S (i.e. formula (I)), whose structural formula was identified via chemical analysis, and characteristic analysis was performed via high performance liquid chromatography (HPLC). The erinacine S was obtained using a reverse chromatography column Cosmosil 5C18-AR-II (Nacalai USA, California, U.S.A.) at 40° C. and eluted using acetonitrile starting from 60 volume % and reaching to 65 volume % within 20 minutes at 1 ml/min of flow rate and 290 nm of the UV detection wavelength. The retention time of the erinacine S is 14 minutes. The HPLC analytic result is shown in
FIG. 1 (where the label is the erinacine S standard). InFIG. 1 , the upper curve indicates the freeze-dried powder of the H. erinaceus mycelia alcohol extract, and the lower curve indicates the erinacine S standard. The erinacine S standard is a standard prepared using the method above by the Applicant, and acts as a quantification basis for the erinacine S in the components of the extract. - The chromatography plot of the prepared alcohol extract in
Embodiment 2 shows that peaks appear at the retention times of 2, 7 and 14 minutes. Comparing the erinacine S standard with the one peak at 14 minutes, it can be determined that the peak indicates erinacine S. The erinacine S in the alcohol extract is quantified as 59 ppm. - The 1H and 12C nuclear magnetic resonance (NMR) of the erinacine S are described in the following table.
-
position δH (multiplicity, J in Hz) δC HMBC (H→C) 1 1.54 (1H, dt, 13.2, 7.8) 38.2 (t) C2, C-3, C-4, C-8, C-9, C-17 1.61 (1H, dt, 13.2, 7.8) 2 2.28 (2H, t, 7.2) 28.4 (t) C-1, C-3, C-4, C-9 3 138.6 (s) 4 139.3 (s) 5 2.64 (1H, d, 9.6) 46.5 (d) C-3, C-4, C-6, C-9, C-10, C-11, C-16 6 42.5 (s) 7 1.80 (2H, m) 28.9 (t) C-5, C-6, C-8, C-9, C-16 8 1.40 (1H, m) 36.8 (t) C-1, C-7, C-9, C-17 1.51 (1H, dd, 12.6, 6.0) 9 49.6 (s) 10 1.69 (1H, m) 25.1 (t) C-4, C-5, C-6, C-11, C-12 2.02 (1H, m) 11 1.99 (1H, m) 32.3 (t) C-12, C-13, C-15 3.76 (1H, m) 12 129.4 (s) 13 3.80 (1H, dd, 10.8, 1.8) 49.1 (d) C-6, C-12, C-14, C-15, C-22, C-23 14 4.40 (1H, d, 10.8) 91.3 (d) C-6, C-7, C-12, C-16 15 142.7 (s) 16 1.11 (3H, s) 19.4 (q) C-5, C-6, C-7, C-14 17 1.07 (3H, s) 25.0 (q) C-1, C-4, C-8, C-9 18 2.77 (1H, septet, 6.6) 27.3 (d) C-2, C-3, C-4, C-19, C-20 19 0.97 (3H, d, 6.6) 21.4 (q) C-3, C-18, C-20 20 0.98 (3H, d, 6.6) 21.9 (q) C-3, C-18, C-19 21 6.13 (1H, s) 113.3 (s) C-13, C-14, C-25 22 93.0 (s) 23 83.2 (s) 24 193.6 (s) 25 4.48 (1H, d, 10.2) 80.8 (t) C-21, C-22, C-23, C-24 4.60 (1H, d, 10.2) 15-OH 10.76 (1H, s) C-12, C-15, C-24 - 1. The incubation of cells:
- Three cell lines, i.e. rat pheochromocytoma cell line PC12, human neuroblastoma cell line SH-SY5Y and human osteosarcoma cell line HOS, were used. PC12 cells were incubated in a Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) horse serum (HS) and 5% (v/v) fetal bovine serum (FBS) (Kao et al., Toxicol. Sci., 2012, 125(2):462-472). Human neuroblastoma SH-SY5Y cells were incubated in a DMEM/F-12 medium supplemented with 10% (v/v) FBS (Liu et al., J. Toxicol. Sci., 2009, 34(3):255-263). HOS cells were incubated in a minimum essential medium (MEM) (containing Earle's salts, 2 mM L-glutamine and 0.1 mM non-essential amino acids) supplemented with 1.5 g/L sodium bicarbonate and 1 mM pyruvate sodium, and an extra 5% (v/v) FBS was added during use. Cells were grown in a 5% CO2 humidified incubator at 37° C. The medium was replaced every 2-3 days, and cells were sub-cultured using trypsin-ethylenediaminetetraacetic acid (EDTA) (Liu et al., Eur. J. Pharmacol., 2011, 650(1):34-40).
- 2. The Detection of P2R mRNA:
- Messenger RNA (mRNA) was extracted from cells to prepare complementary DNA (cDNA). Specific primers for individual P2R subtype receptors were designed, wherein SEQ ID NOs: 1˜2, 3˜4, 5˜6, 7˜8, 9˜10, 11˜12 and 13˜14 respectively are primers for human P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7 subtype receptors, SEQ ID NOs: 15˜16, 17˜18, 19˜20, 21˜22, 23˜24, 25˜26, 27˜28 and 29˜30 respectively are primers for human P2Y1, P2Y2, P2Y4, P2Y5, P2Y6, P2Y9, P2Y10 and P2Y11 subtype receptors, SEQ ID NOs: 31˜32 are primers for human β-actin, SEQ ID NOs: 33˜34, 35˜36, 37˜38, 39˜40, 41˜42, 43˜44 and 45˜46 respectively are primers for rat P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7 subtype receptors, SEQ ID NOs: 47˜48, 49˜50, 51˜52, 53˜54, 55˜56, 57˜58 and 59˜60 respectively are primers for rat P2Y1, P2Y2, P2Y4, P2Y6, P2Y12, P2Y13 and P2Y14 subtype receptors, and SEQ ID NOs: 61˜62 are primers for rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and the mRNA expressions of the P2R subtype receptors were amplified using polymerase chain reaction (PCR) and monitored. At first, cells were washed with phosphate buffered saline (PBS), and mRNA was obtained in the column using a NucleoSpin® RNA II kit (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany), and the concentration of RNA was determined using an ACTGene ASP-2680 spectrophotometer (CellTAGen, Seoul, Republic of Korea). Furthermore, the reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using SuperScript® III Reverse Transcriptase (Invitrogen™, ThermoFisher Scientific, Waltham, Mass., U.S.A.). mRNA was reverse-transcribed as cDNA, and then PCR was performed on this cDNA using a Q-
Amp™ 2× HotStart PCR master mix (containing Taq DNA polymerase) (Bio-Genesis Technologies, Inc., Taiwan) and the P2R primers. The obtained PCR product was electrophoresed in 1.5% (w/v) agarose gel in the buffer (containing 0.5×Tris-borate EDTA (TBE)) in an electrophoresis tank. The voltage during the electrophoresis was set at 50 V, and the voltage was increased to 100 V for 15 minutes. After electrophoresis, the agarose gel was stained with ethidium bromide (EtBr), and then was transferred to a gel image system to be illuminated by ultraviolet (UV) radiation. The gel image was recorded, and the P2R expressed by the cells was observed. - The gene expressions of P2R in the rat pheochromocytoma cell line PC12, human neuroblastoma cell line SH-SY5Y and human osteosarcoma cell line HOS were determined using RT-PCR.
FIGS. 2(A), 2(C) and 2(E) show the mRNA expressions of the P2X subtype receptors,FIGS. 2(B), 2(D) and 2(F) show the mRNA expressions of the P2Y subtype receptors, and HOS, SH-SY5Y or PC12 in the lower left corner in each panel is the cell line's name. It can be seen that the P2XR subtypes (i.e. P2X1R, P2X4R, P2X5R, P2X6R and P2X7R) and the P2YR subtypes (i.e. P2Y1R, P2Y2R, P2Y4R, P2Y6R and P2Y11R) were detected in the human osteosarcoma cell line HOS, the P2XR subtypes (i.e. P2X3R, P2X4R, P2X5R, P2X6R and P2X7R) and the P2YR subtypes (i.e. P2Y1R, P2Y2R, P2Y4R and P2Y11R) were detected in the human neuroblastoma cell line SH-SY5Y, and the P2XR subtypes (i.e. P2X2R, P2X3R and P2X4R) and the P2YR subtype (i.e. P2Y12R) were detected in the rat neuronal cell line PC12. - 1. The P2R-Correlated Calcium Signals Detected in the Cell Lines:
- The rat pheochromocytoma cell line PC12, human neuroblastoma cell line SH-SY5Y and human osteosarcoma cell line HOS were filled with Fura-2 calcium ion-sensitive fluorescent dye to detect the intracellular free calcium-ion concentration. Furthermore, the P2R on the cell membrane was stimulated using ATP to observe the variations of the intracellular free calcium-ion concentration.
FIGS. 3(A), 3(B) and 3(C) show the variations of the calcium signals of the receptors in (A) human osteosarcoma HOS cells, (B) rat pheochromocytoma PC12 cells and (C) human neuroblastoma SH-SY5Y cells after being stimulated with 0.1 mM ATP. The intracellular free calcium-ion concentration in human neuroblastoma SH-SY5Y cells did not vary. To exclude the possibility that cells do not generate bio-molecules which are correlated to calcium-ion signals, the acetylcholine receptor on the human neuroblastoma SH-SY5Y cells was further stimulated with 0.1 mM carbachol to confirm that the cells do have molecules which are correlated to calcium-ion signals, and the results are shown inFIG. 3(C) . - 2. Calcium Signals Correlated to the Individual P2R Subtypes:
- Comparing the P2R-correlated calcium signals in three cell lines stimulated with ATP, the variation of the calcium-ion concentration in human osteosarcoma HOS cells was the most significant, and thus the influence of the agent on P2R can clearly be determined. Therefore, human osteosarcoma HOS cells were selected as the sample to further detect the P2R subtypes which may be correlated with calcium signals in human osteosarcoma HOS cells. The 2-methylene ATP (2-MeATP, the selective stimulator for the P2X1R and P2X5R subtypes), α,β-methylene ATP (α,β-MeATP, the selective stimulator for the P2X7 subtype), 2-(methylthio)
adenosine 5′-triphosphate (2-MeSATP, the selective stimulator for the P2X1 subtype) andcytosine 5′-triphosphate (CTP, the selective stimulator for the P2X4 subtype) were used to determine the P2R subtypes in human osteosarcoma HOS cells. The curves from left to right inFIG. 4 show the calcium-ion signals induced by the specific stimulators (CTP, 2-MeATP, α,β-MeATP and 2-MeSATP) for the subtype receptors, indicating that at least the calcium signals correlated with P2X1, P2X4, P2X5 and P2Y7 can be detected in human osteosarcoma HOS cells, and the reaction for P2X4 is the most significant. - The P2Y receptor is correlated with the G-protein (Gq). The Gq can be activated after stimulating the receptor, to further activate phospholipase C so as to generate
inositol FIGS. 5(A) and 5(B) show the calcium signals correlated with the P2Y receptor, whereinFIG. 5(A) shows that the calcium signals are induced by using ATP to stimulate the P2R in a calcium ion free buffer, and this is a response for the P2R receptor-correlated calcium signals because no extracellular calcium ions flow into the cells; andFIG. 5(B) shows the calcium signals induced using the uridine triphosphate (UTP) to stimulate cells. It is shown inFIGS. 5(A) and 5(B) that at least the P2Y2R- and P2Y4R-correlated calcium signals can be detected in human osteosarcoma HOS cells. - 3. The P2R-Correlated Calcium Signals Inhibited by the Active Substances of H. erinaceus:
- ATP is a stimulator for P2R in the body, and thus 0.1 mM ATP is used to stimulate the P2R receptor. The H. erinaceus alcohol extract was added before the calcium signals were induced using ATP to stimulate the P2R. A secondary signal is equivalent to a physiological reaction after a receptor is stimulated. Therefore, it can be seen in
FIG. 6 that the P2R's calcium signals induced by ATP are completed inhibited, and it is proved that P2R's functions can be inhibited by the H. erinaceus alcohol extract. It is proved in the above experiments that there are a variety of P2XRs and P2YRs on the HOS cells and the functions of the P2R receptors can be completely inhibited by the H. erinaceus alcohol extract, and it is determined that the H. erinaceus alcohol extract has an inhibition effect on receptors such as P2X1, P2X4, P2X5, P2Y7, P2Y2, P2Y4 receptors and so on. - 4. the Correlation Between the Inhibition Functions of the H. erinaceus Active Substances and the Erinacine S and their Concentrations:
-
FIGS. 7(A) and 7(B) show the inhibition effect of (A) the H. erinaceus alcohol extract of 2.5, 5 and 50 μg/ml and (B) the erinacine S of 5, 10 and 15 μg/ml on the variation of the intracellular calcium-ion concentration in human osteosarcoma HOS cells induced using the ATP to stimulate the P2R receptor, and the inhibition effect is more significant in a dosage-dependent manner, indicating that the dosage given is correlated with the inhibition effect. - This embodiment was performed to observe the mice's pain reaction to the extrinsic stimulation before/after administration via the tail flick test and the hot-plate test, after the mice were administered with the H. erinaceus active substances (i.e. the alcohol extract obtained in
Embodiment 2 and the alcohol extraction mixture obtained in Embodiment 3) for a short term or a long term. - 1. The Tail Flick Test after the H. erinaceus Active Substances were Administered for a Short Term:
- Mice in this experiment were divided into three groups, i.e. the control group, the H. erinaceus mycelia/alcohol extract (the alcohol extraction mixture group), and the H. erinaceus alcohol extract (the alcohol extract group). Each group had five male C57BL/6 Narl mice which were older than eight weeks old. The mice were orally administered with 2500 mg/kg of drugs via a soft feeding tube, and the mice in the control group were fed with an equal amount of water. The mouse's nociception was determined by the tail flick test before administration, and 30 and 60 minutes after administration. The experimental results were expressed as mean±standard deviation, and the significance of statistics among the alcohol extraction mixture group, the alcohol extract group and the control group was analyzed using Student's t-test. Therefore, the pain-relieving effect of administering the active substances for a short term can be observed, and the results are shown in
FIG. 8 . - The tail-flick basic values were examined before administration, the tail-flick reaction time in three groups was 4.1±1.5 seconds (s) in the control group, 4.3±1.9 s in the alcohol extraction mixture group, and 4.5±1.2 s in the alcohol extract group. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.8, the p-value for Student's t-test between the alcohol extract group and the control group was 0.6, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.8, indicating that there was no significant difference between groups before administration.
- The mouse's nociception reaction was determined by the
tail flick test 30 minutes after administration. The experimental results show that the tail flick reaction time was 2.0±0.5 s in the control group, 6.2±1.6 s in the alcohol extraction mixture group, and 8.4±1.1 s in the alcohol extract group. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.0008 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.000009 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.07 without a significant difference. - The mouse's nociception reaction was determined by the
tail flick test 60 minutes after administration. The experimental results showed that the tail-flick reaction time was 2.1±0.57 s in the control group, 5.7±2.46 s in the alcohol extraction mixture group, and 7.2±1.9 s in the alcohol extract group. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.0256 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.0016 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.33 without a significant difference. - 2. The Difference in the Tail Flick Test Before/after Administration with the H. erinaceus Active Substances for a Short Term:
- The experimental conditions are similar to the condition in the subsection “1. The tail flick test after the H. erinaceus active substances was administered for a short term”, and the difference of the tail-flick reaction times among the alcohol extract group, the alcohol extraction mixture group and the control group was compared. Therefore, the pain-relieving effect of administering the active substances for a short term can be observed, and the results are shown in
FIG. 9 . - The mouse's nociception reaction was determined by the
tail flick test 30 minutes after administration. The experimental results show that the tail-flick reaction time in the control group was shorter compared to the tail-flick basic value before administration, with a difference of −2.1±1.7 s; the tail-flick reaction time in the alcohol extraction mixture group was longer compared to that before administration, with a difference of 2.6±2.18 s; and the tail-flick reaction time in the alcohol extract group was longer compared to that before administration, with a difference of 3.9±1.61 s. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.008 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.00108 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.35 without a significant difference. - The mouse's nociception reaction was determined by the
tail flick test 60 minutes after administration. The experimental results show that the tail-flick reaction time in the control group was shorter compared to the tail-flick basic value before administration, with a difference of −1.0±0.71 s; the tail-flick reaction time in the alcohol extraction mixture group was longer compared to that before administration, with a difference of 2.0±2.53 s; and the tail-flick reaction time in the alcohol extract group was longer compared to that before administration, with a difference of 2.6±1.77 s. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.033 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.0028 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.66 without a significant difference. - 3. The Maximum Possible Effects in the Tail Flick Test after Administration of the H. erinaceus Active Substances for a Short Term
- The conditions of this experiment are similar to those in the subsection “1. The tail flick test after the H. erinaceus active substances was administered for a short term” above, and the maximum possible effects (MPE) are calculated as follows. The tail-flick reaction time after administration minus the tail-flick reaction time before administration (a tail-flick basic value for a single mouse) have a difference, and then the difference divided by the tail-flick basic value for this single mouse is the MPE. Therefore, the pain-relieving effect of administering the active substances for a short term can be observed, and the results are shown in
FIG. 10 . - The mouse's nociception reaction was determined by the
tail flick test 30 minutes after administration. The experimental results show that the tail-flick reaction time in the control group was shorter (about half) compared to the tail-flick basic value before administration; the tail-flick reaction time in the alcohol extraction mixture group was longer compared to that before administration; and the tail-flick reaction time in the alcohol extract group was longer by about one time compared to that before administration. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.03 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.0134 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.31 without a significant difference. - The mouse's nociception reaction was determined by the
tail flick test 60 minutes after administration. The experimental results show that the tail-flick reaction time in the control group was shorter compared to the tail-flick basic value before administration; the tail-flick reaction time in the alcohol extraction mixture group was longer by about one time compared to that before administration; and the tail-flick reaction time in the alcohol extract group was longer compared to that before administration. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.05 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.004 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.61 without a significant difference. It is predicted that the H. erinaceus active substances have an immediate pain-relieving effect which can at least continue for about 60 minutes. - 4. The Hot-Plate Test after Administration of the H. erinaceus Active Substances for a Long Term:
- This assay is used to determine whether the administration of the H. erinaceus active substances for a long term can delay in response caused by the hot plate. Each mouse was fed with 2500 mg/kg active substance for three days, and the interval between two feeds was 24 hours. Next, the hot-plate test was performed after feeding the active substances for three days, the amounts of paw lifting, licking or jumping were determined and the results are shown in
FIG. 11 . - After administration for three days, the experimental results show that the paw withdrawal reaction time was 6.4±1.8 s in the control group, 11.7±2.5 s in the alcohol extraction mixture group, and was 11.5±1.8 s in the alcohol extract group. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.005 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.0025 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.09 without a significant difference.
- 30 minutes after performing the first-time hot-plate test on
administration day 3, the paw withdrawal reaction time was determined again with the same experimental method. The experimental results show that the paw withdrawal reaction time was 6.3±0.8 s in the control group, 11.8±2.5 s in the alcohol extraction mixture group, and was 8.9±1.2 s in the alcohol extract group. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.007 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.010 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.09 without significant difference. - After calculating the first-determination data after feeding for 3 days and the data from the after-30-minutes determination, the experimental results show that the paw withdrawal reaction time was 5.7±2.4 s in the control group, 11.7±2.3 s in the alcohol extraction mixture group, and was 10.3±2.0 s in the alcohol extract group. The p-value for Student's t-test between the alcohol extraction mixture group and the control group was 0.00006 with a significant difference, the p-value for Student's t-test between the alcohol extract group and the control group was 0.0003 with a significant difference, and the p-value for Student's t-test between the alcohol extraction mixture group and the alcohol extract group was 0.81 without a significant difference.
- According to this animal experiment, it can be seen that the alcohol extraction mixture and the alcohol extract have significant pain-relieving effects on a short-term reaction after a 30-minute administration, and the pain-relieving effect tended to decline after a 60-minute administration. In the experiment where the alcohol extraction mixture and alcohol extract were fed for a long term, deallergization occurs and the pain-relieving effect tends to stabilize.
- In conclusion, the H. erinaceus active substances including the H. erinaceus mycelia, the H. erinaceus alcohol extract, the H. erinaceus alcohol extraction mixture and the erinacine S disclosed in the present invention have been proven to have the pain-relieving effect, and can be widely used for pain relief.
Claims (21)
1.-24. (canceled)
25. A preparation method for an active substance of a Hericium erinaceus for relieving a pain, comprising:
(a) inoculating an H. erinaceus mycelium on an agar plate to be incubated;
(b) inoculating the incubated mycelium in step (a) into a first medium on a small scale to be incubated; and
(c) inoculating the incubated mycelium in step (b) into a second medium on a large scale to be incubated to obtain a fermented medium containing the active substance.
26. The preparation method according to claim 25 , wherein the incubation in step (a) is performed at 15-32° C. for 8-16 days.
27. The preparation method according to claim 25 , wherein the incubation in step (b) is performed at 20-30° C., pH 4.5-6.5, and a shaking rate of 100-250 rounds per minutes (rpm) for 3-5 days.
28. The preparation method according to claim 25 , wherein in step (c) the second medium on the large scale is accommodated in a fermentation tank having a tank pressure of 0.8-1.2 kg/cm2 and a stirring rate of 10-150 rpm, a gas is introduced into the fermentation tank at an aeration rate of 0.5-1 volume per volume per minute (vvm), the gas is one selected from a group consisting of air, oxygen, carbon dioxide, nitrogen gas and a combination thereof, and the incubation is performed at 24-32° C. and pH 4.5-5.5 for 8-16 days.
29. The preparation method according to claim 25 , wherein the first and the second media are the same.
30. The preparation method according to claim 29 , wherein each of the first and the second media comprises one selected from a group consisting of a complex carbon and nitrogen source, animal or plant sources of one of a protein and a hydrolyzate thereof, an inorganic salt, a saccharide, a yeast extract, a malt extract, a defoaming agent and a combination thereof, and the complex carbon and nitrogen source is one of a grain and a legume, and the inorganic salt is one of a sulfate and a phosphate.
31. The preparation method according to claim 25 , wherein the preparation method further comprises (d) desiccating the fermented medium to obtain a powder of the H. erinaceus mycelium.
32. The preparation method according to claim 31 , wherein the powder is further extracted with an alcohol solution to obtain an alcohol extract of the H. erinaceus mycelium, and the alcohol solution is an ethanol solution of 30-100 volume-volume percentage (v/v %) or a methanol solution of 30-100 (v/v %).
33. The preparation method according to claim 32 , wherein the alcohol extract is further extracted with water-ethyl acetate, followed by a column chromatography to obtain a heripene having a formula (I) as follows:
where R is one selected from a group consisting of hydrogen, hydroxyl, C1-C10 alkyl, C2-C10 alkenyl and C2-C10 alkynyl, each of which is optionally substituted with a substitute bonding with one selected from a group consisting of halogen, oxygen, nitrogen, phosphorus and sulfur, and where the stereocenters at C-5, C-6, C-9, C-13, C-14, C-21, C22 and C-23 are one of an R configuration and an S configuration.
35. The preparation method according to claim 33 , wherein the water-ethyl acetate has a ratio of 1:4 (v/v).
36. The preparation method according to claim 25 , wherein the pain is one of a neuropathic pain and a cancer pain.
37. The preparation method according to claim 36 , wherein the pain involves a signaling pathway with regard to a P2-purinoceptor (P2R).
38. An active substance of a Hericium erinaceus for relieving a pain as obtained according to claim 25 .
39. The active substance according to claim 38 , wherein the active substance is obtained in a form of a powder.
40. The active substance according to claim 39 , wherein the powder is extracted as one of an alcohol extract and a heripene having a formula (I) as follows:
where R is one selected from a group consisting of hydrogen, hydroxyl, C1-C10 alkyl, C2-C10 alkenyl and C2-C10 alkynyl, each of which is optionally substituted with a substitute bonding with one selected from a group consisting of halogen, oxygen, nitrogen, phosphorus and sulfur, and where the stereocenters at C-5, C-6, C-9, C-13, C-14, C-21, C22 and C-23 are one of an R configuration and an S configuration.
42. A pharmaceutical composition for a pain-relieving effect, comprising an active substance of a Hericium erinaceus according to claim 36 , and one selected from a group consisting of a biologically acceptable carrier, an excipient, a diluent and an adjuvant.
43. A heripene compound for a pain-relieving effect, including a formula (I) as follows:
where R is one selected from a group consisting of hydrogen, hydroxyl, C1-C10 alkyl, C2-C10 alkenyl and C2-C10 alkynyl, each of which is optionally substituted with a substitute bonding with one selected from a group consisting of halogen, oxygen, nitrogen, phosphorus and sulfur; and
where the stereocenters at C-5, C-6, C-9, C-13, C-14, C-21, C22 and C-23 are one of an R configuration and an S configuration.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/088813 WO2017035801A1 (en) | 2015-09-02 | 2015-09-02 | Heripene having pain reduction efficacy, hericium erinaceus mycelium active substance, preparation method for active substance, and pharmaceutical composition including active substance |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/088813 A-371-Of-International WO2017035801A1 (en) | 2015-09-02 | 2015-09-02 | Heripene having pain reduction efficacy, hericium erinaceus mycelium active substance, preparation method for active substance, and pharmaceutical composition including active substance |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/674,209 Continuation US11648233B2 (en) | 2015-09-02 | 2019-11-05 | Heripenes with pain-relieving effect, active substances of Hericium erinaceus mycelium and the preparation method thereof, and pharmaceutical composition containing the heripenes or active substances |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170312247A1 true US20170312247A1 (en) | 2017-11-02 |
Family
ID=58186658
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/508,369 Abandoned US20170312247A1 (en) | 2015-09-02 | 2015-09-02 | HERIPENES WITH PAIN-RELIEVING EFFECT, ACTIVE SUBSTANCES OF Hericium erinaceus MYCELIUM AND THE PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE HERIPENES OR ACTIVE SUBSTANCES |
US16/674,209 Active 2037-01-05 US11648233B2 (en) | 2015-09-02 | 2019-11-05 | Heripenes with pain-relieving effect, active substances of Hericium erinaceus mycelium and the preparation method thereof, and pharmaceutical composition containing the heripenes or active substances |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/674,209 Active 2037-01-05 US11648233B2 (en) | 2015-09-02 | 2019-11-05 | Heripenes with pain-relieving effect, active substances of Hericium erinaceus mycelium and the preparation method thereof, and pharmaceutical composition containing the heripenes or active substances |
Country Status (4)
Country | Link |
---|---|
US (2) | US20170312247A1 (en) |
JP (1) | JP6757405B2 (en) |
CN (1) | CN108347886B (en) |
WO (1) | WO2017035801A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113303168A (en) * | 2021-07-13 | 2021-08-27 | 河南农业大学 | Application of EGTA in calcium-rich and cadmium-reducing capacity of synergistic calcium chloride in mushroom culture |
US11708346B2 (en) | 2019-07-23 | 2023-07-25 | Saint Louis University | Treatment and prevention of neuropathic pain with P2Y14 antagonists |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102686642B1 (en) * | 2021-07-13 | 2024-07-22 | 주식회사 케이제이엠바이오 | Method for manufacturing powder containing fermented product of aloe hericium erinacium mycelium and functional food composition comprising the powder manufactured accordingly |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101455354A (en) * | 2007-12-14 | 2009-06-17 | 中国科学院微生物研究所 | Natural Juncao liver-nourishing and sobering-up agent |
JP5354532B2 (en) * | 2009-03-30 | 2013-11-27 | 学校法人福岡大学 | Yamabushitake extract and method for producing the same |
CN101829159B (en) * | 2010-06-03 | 2012-07-04 | 樊美珍 | Method for preparing selenium-enriched monkey head mushroom capsule |
JP2014223051A (en) * | 2012-07-13 | 2014-12-04 | タカラバイオ株式会社 | Method for producing of ergothioneine |
TWI516598B (en) * | 2013-03-21 | 2016-01-11 | Grape King Inc | A method for preventing the rapid degradation of Hericium erinaceus A during the fermentation of mycelium of Hericium erinaceus |
CN103651657B (en) * | 2013-08-09 | 2015-03-04 | 江西江中制药(集团)有限责任公司 | Health-care flour composition and food |
CN104072593A (en) * | 2014-07-03 | 2014-10-01 | 江苏大学 | Hericium erinaceus glycoprotein with anti-tumor and agglutination activity and preparation method thereof |
CN104497059B (en) * | 2014-12-29 | 2017-04-12 | 浙江工业大学 | Extraction method of total erinacine in hericium erinaceus mycelium |
-
2015
- 2015-09-02 CN CN201580000569.0A patent/CN108347886B/en active Active
- 2015-09-02 WO PCT/CN2015/088813 patent/WO2017035801A1/en active Application Filing
- 2015-09-02 JP JP2018511429A patent/JP6757405B2/en active Active
- 2015-09-02 US US15/508,369 patent/US20170312247A1/en not_active Abandoned
-
2019
- 2019-11-05 US US16/674,209 patent/US11648233B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11708346B2 (en) | 2019-07-23 | 2023-07-25 | Saint Louis University | Treatment and prevention of neuropathic pain with P2Y14 antagonists |
CN113303168A (en) * | 2021-07-13 | 2021-08-27 | 河南农业大学 | Application of EGTA in calcium-rich and cadmium-reducing capacity of synergistic calcium chloride in mushroom culture |
Also Published As
Publication number | Publication date |
---|---|
WO2017035801A1 (en) | 2017-03-09 |
CN108347886B (en) | 2020-05-15 |
JP2018530316A (en) | 2018-10-18 |
CN108347886A (en) | 2018-07-31 |
US20200068815A1 (en) | 2020-03-05 |
US11648233B2 (en) | 2023-05-16 |
JP6757405B2 (en) | 2020-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11648233B2 (en) | Heripenes with pain-relieving effect, active substances of Hericium erinaceus mycelium and the preparation method thereof, and pharmaceutical composition containing the heripenes or active substances | |
Davis | Ethanol–BDNF interactions: still more questions than answers | |
CN109641135A (en) | Beta-hydroxy-Beta-methyl butyric acid (HMB) is used to adjust the composition and method of autophagy and lipophagia | |
Zafra et al. | Glycinergic transmission: glycine transporter GlyT2 in neuronal pathologies | |
CN106632601B (en) | Short peptide for blocking synapse long-term potentiation (LTP) and application thereof | |
Liu et al. | Lion's mane medicinal mushroom, Hericium erinaceus (Agaricomycetes), modulates purinoceptor-coupled calcium signaling and murine nociceptive behavior | |
Lan et al. | Modulatory effect of glutamate GluR2 receptor on the caudal neurosecretory Dahlgren cells of the olive flounder, Paralichthys olivaceus | |
WO2020094002A1 (en) | Antiepileptic toxin martentoxin and use thereof | |
Xiong et al. | MicroRNA339 targeting PDXK improves motor dysfunction and promotes neurite growth in the remote cortex subjected to spinal cord transection | |
Wang et al. | Olfr78, a novel short‐chain fatty acid receptor, regulates glucose homeostasis and gut GLP‐1 secretion in mice | |
US20100048594A1 (en) | Use of cytohesin inhibitors for chemically inducing longevity | |
TW201702382A (en) | Hericium erinaceus having an effect of pain relief, Hericium erinaceus mycelium active substance, preparation method thereof, and pharmaceutical composition containing the same to obtain a novel compound of heripene having an effect of pain relief | |
KR20190080877A (en) | Organoselenium compound-containing composition | |
KR101204427B1 (en) | Composition comprising Ganoderma lucidum extracts for DPP-IV inhibition | |
Chen et al. | Effects of 919 syrup and D101 on immobilization stress response in postpartum mice | |
KR102637692B1 (en) | Antiviral composition against hepatitis B virus comprising inhibitor of DEAD-box protein | |
CN110564771B (en) | Preparation method of cerebral calcification disease model | |
JP7359377B2 (en) | Oxytocin production promoter | |
TWI564015B (en) | Use of treating or preventing hyperglycemia, hyperlipidemia, and hepatic fat accumulation with ergostatrien-3β-ol from antrodia camphorata | |
KR20120060192A (en) | Composition for ameliorating the ER stress or the mitochondrial dysfunction comprising the extract of Angelica dahurica or imperatorin | |
KR20130044256A (en) | Composition for ameliorating the er stress or the mitochondrial dysfunction comprising the extract of angelica dahurica or imperatorin | |
Begani | Role of LANCL1 and LANCL2 in the physiology and biochemistry of myocytes and cardiomyocytes. | |
JP2023135605A (en) | Prepro-orexin as bioactive peptide, fragments thereof, and variants thereof | |
Pan et al. | EGFR core fucosylation, induced by enveloped viruses, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses | |
Yu et al. | Rodent models in Down syndrome research: impact and future opportunities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GRAPE KING BIO LTD., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, PEI-SHAN;CHEN, CHIEN-CHIH;CHEN, CHIN-CHU;AND OTHERS;REEL/FRAME:041444/0958 Effective date: 20161219 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |